UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 20182019

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from________ to_________.

 

Commission File Number: 001-38389

 

001-38389

Motus GI Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 81-4042793
(State or other jurisdiction of
incorporation or organization)
 

(I.R.S. Employer


Identification Number)

1301 East Broward Boulevard, 3rd Floor


Ft. Lauderdale, FL

 33301
(Address of principal executive offices) (Zip code)

 

(786) 459 1831(954) 541 8000

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of Each Exchanged on Which Registered
Common Stock, $0.0001 par value per shareMOTSThe Nasdaq Capital Market

As of October 31, 2018, 15,690,151November 6, 2019, 28,796,017 shares of the registrant’s common stock, $0.0001 par value, were issued and outstanding.

 

 

 

MOTUS GI HOLDINGS, INC.

 

Quarterly Report on Form 10-Q for the Quarter Ended September 30, 20182019

 

TABLE OF CONTENTS

 

 Page Page
PART I PART I 
   
FINANCIAL INFORMATION FINANCIAL INFORMATION 
    
1.Unaudited Condensed Consolidated Financial Statements1Unaudited Condensed Consolidated Financial Statements1
Condensed Consolidated Balance Sheets as of September 30, 2018 (unaudited) and December 31, 20171
Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2017 (unaudited)2Condensed Consolidated Balance Sheets as of September 30, 2019 (unaudited) and December 31, 20181
Condensed Consolidated Statement of Changes in Shareholders’ Equity (Deficit) for the Nine-Month Period Ended September 30, 2018 (unaudited) 3 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited)2
Condensed Consolidated Statement of Changes in Shareholders’ Equity (Deficit) for the Nine-Month Period Ended September 30, 2017 (unaudited)4Condensed Consolidated Statement of Changes in Shareholders’ Equity for the Nine Months Ended September 30, 2019 (unaudited)3
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017 (unaudited)5Condensed Consolidated Statement of Changes in Shareholders’ Equity for the Nine Months Ended September 30, 2018 (unaudited)4
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2019 and 2018 (unaudited)5
Notes to the Unaudited Interim Condensed Consolidated Financial Statements6Notes to the Unaudited Interim Condensed Consolidated Financial Statements6
2.Management’s Discussion and Analysis of Financial Condition and Results of Operations22Management’s Discussion and Analysis of Financial Condition and Results of Operations24
3.Quantitative and Qualitative Disclosures about Market Risk28Quantitative and Qualitative Disclosures about Market Risk31
4.Controls and Procedures28Controls and Procedures31
    
PART II PART II 
   
OTHER INFORMATION OTHER INFORMATION 
    
1.Legal Proceedings30Legal Proceedings33
1A.Risk Factors30Risk Factors33
2.Unregistered Sales of Equity Securities and Use of Proceeds30Unregistered Sales of Equity Securities and Use of Proceeds33
3.Defaults Upon Senior Securities31Defaults Upon Senior Securities33
4.Mine Safety Disclosures31Mine Safety Disclosures33
5.Other Information31Other Information33
6.Exhibits32Exhibits34

 

i

 

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

 

Motus GI Holdings, IncInc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

    
 September 30, December 31, September 30, December 31, 
 2018 2017 2019  2018 
  (unaudited)   (*)  (unaudited) (*) 
             
ASSETS             
             
Current assets             
Cash and cash equivalents $6,887  $6,939  $15,717  $18,050 
Short-term investments  4,744    
Investments  10,657   3,043 
Accounts receivable  23   5   -   5 
Inventory  46   6   771   23 
Prepaid expenses and other current assets  1,188   734   537   930 
Deferred financing fees  59   602 
Total current assets  12,947   8,286   27,682   22,051 
                
Fixed assets, net  871   783   1,015   846 
Other long-term assets  88   99 
Right-of-use assets  1,056   - 
Other non-current assets  13   57 
                
Total assets $13,906  $9,168  $29,766  $22,954 
                
LIABILITIES AND SHAREHOLDERS’ EQUITY                
                
Current liabilities                
Accounts payable and accrued expenses $2,416  $1,733  $2,733  $2,140 
Operating lease liabilities - current  320   - 
Other current liabilities  58   250   494   253 
Total current liabilities  2,474   1,983   3,547   2,393 
                
Contingent royalty obligation  1,906   1,662   1,885   1,953 
Operating lease liabilities - non-current  748   - 
Other non-current liabilities  84      -   91 
                
Total liabilities  4,464   3,645   6,180   4,437 
                
Shareholders’ equity                
Common Stock $0.0001 par value; 50,000,000 shares authorized; 15,690,151 and 10,493,233 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively  2   1 
Preferred Series A stock $0.0001 par value; 2,000,000 shares authorized; 0 and 1,581,128 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively      
        
Preferred stock $0.0001 par value; 8,000,000 shares authorized; zero shares issued and outstanding      
Preferred Stock $0.0001 par value; 8,000,000 shares authorized; zero shares issued and outstanding  -   - 
Preferred Series A Stock $0.0001 par value; 2,000,000 shares authorized; zero shares issued and outstanding  -   - 
Common Stock $0.0001 par value; 50,000,000 shares authorized; 28,796,017 and 21,440,148 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively  3   2 
Additional paid-in capital  65,251   44,643   102,110   79,893 
Accumulated deficit  (55,811)  (39,121)  (78,527)  (61,378)
Total shareholders’ equity  9,442   5,523   23,586   18,517 
                
Total liabilities and shareholders’ equity $13,906  $9,168  $29,766  $22,954 

 

(*) Derived from audited consolidated financial statements

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


Motus GI Holdings, IncInc.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands, except share and per share amounts)

(unaudited)

 

 Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
 2018 2017 2018 2017 2019  2018  2019  2018 
                 
Revenue $  $  $38  $  $3  $-  $8  $38 
Cost of revenue        56      62   -   65   56 
Gross loss        (18)     (59)  -   (57)  (18)
                                
Operating expenses:                                
Research and development  1,770   965   4,357   2,701   2,173   1,770   6,706   4,357 
Sales and marketing  1,215   614   2,945   1,603   1,160   1,215   3,473   2,945 
General and administrative  2,145   2,414   6,021   4,907   2,028   2,145   7,189   6,021 
                                
Total operating expenses  5,130   3,993   13,323   9,211   5,361   5,130   17,368   13,323 
                                
Operating loss  (5,130)  (3,993)  (13,341)  (9,211)  (5,420)  (5,130)  (17,425)  (13,341)
                                
Warrant expense        (3,156)     -   -   -   (3,156)
Loss on change in fair value of contingent royalty obligation  (85)  (72)  (244)  (207)
Gain (loss) on change in estimated fair value of contingent royalty obligation  127   (85)  68   (244)
Finance income, net  44      73      95   44   214   73 
Reversal of registration rights expense     900       
Foreign currency gain (loss)  1      (22)  (9)  3   1   (6)  (22)
                                
Loss before income taxes  (5,170)  (3,165)  (16,690)  (9,427)  (5,195)  (5,170)  (17,149)  (16,690)
                                
Income tax expense              -   -   -   - 
                                
Net loss $(5,170) $(3,165) $(16,690) $(9,427) $(5,195) $(5,170) $(17,149) $(16,690)
Basic and diluted loss per common share $(0.33)  (0.30) $(1.13) $(0.92) $(0.18) $(0.33) $(0.72) $(1.13)
Weighted average number of common shares outstanding, basic and diluted  15,680,750   10,489,822   14,782,285   10,288,895   28,716,213   15,680,750   23,896,843   14,782,285 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 


Motus GI Holdings, IncInc.

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Deficit)

Nine-Month PeriodNine Months Ended September 30, 20182019

(In thousands, except share and per share amounts)

(unaudited)

  Preferred Stock  Preferred Series A stock  Common Stock  Additional paid-in  Accumulated  Total shareholders’ equity 
  Shares  Amount  Shares  Amount  Shares  Amount  capital  deficit  (deficit) 
                                     
Balance at January 1, 2018    $   1,581,128  $   10,493,233  $1  $44,643  $(39,121) $5,523 
Issuance of common shares upon initial public offering, net of offering costs              3,500,000   1   14,953      14,954 
Conversion of preferred shares to commons shares in connection with initial public offering        (1,581,128)     1,581,128             
Issuance of common shares upon exercise of over-allotment              56,000      258      258 
Issuance of common shares upon cashless exercise of options              394             
Share based compensation              15,000      602      602 
Warrant expense                    3,156      3,156 
Net loss                       (7,323)  (7,323)
Balance at March 31, 2018              15,645,755   2   63,612   (46,444)  17,170 
Share based compensation                    498      498 
Net loss                       (4,197)  (4,197)
Balance at June 30, 2018              15,645,755   2   64,110   (50,641)  13,471 
Issuance of common shares upon exercise of options              14,396      48      48 
Share based compensation               30,000      1,093      1,093 
Net loss                       (5,170)  (5,170)
Balance at September 30, 2018    $     $   15,690,151  $2  $65,251  $(55,811) $9,442 

  Common Stock  Additional paid-in  Accumulated  Total shareholders’ 
  Shares  Amount  capital  deficit  equity 
Balance at January 1, 2019  21,440,148  $2  $79,893  $(61,378) $18,517 
Issuance of common shares upon exercise of options  416   -   2   -   2 
Issuance of common shares upon vesting of restricted stock units  10,313   -   -   -   - 
Share based compensation  -   -   837   -   837 
Net loss  -   -   -   (6,273)  (6,273)
Balance at March 31, 2019  21,450,877   2   80,732   (67,651)  13,083 
Share based compensation  -   -   690   -   690 
Net loss  -   -   -   (5,681)  (5,681)
Balance at June 30, 2019  21,450,877   2   81,422   (73,332)  8,092 
Issuance of common shares upon public offering, net of offering costs of $1,759  6,666,667   1   18,240   -   18,241 
Issuance of common shares upon exercise of overallotments, net of offering costs of $156  648,333   -   1,789   -   1,789 
Issuance of common shares upon vesting of restricted stock units  30,140   -   -   -   - 
Share based compensation  -   -   659   -   659 
Net loss  -   -   -   (5,195)  (5,195)
Balance at September 30, 2019  28,796,017  $3  $102,110  $(78,527) $23,586 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


Motus GI Holdings, IncInc.

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Deficit)

Nine-Month PeriodNine Months Ended September 30, 20172018

(In thousands, except share and per share amounts)

(unaudited)

 Preferred Stock  Preferred Series A Stock  Common Stock  Additional paid-in  Accumulated  Total shareholders’ equity  Preferred Series A Stock Common Stock Additional paid-in Accumulated Total shareholders’ 
 Shares  Amount  Shares  Amount  Shares  Amount  capital  deficit  (deficit)  Shares Amount Shares Amount capital deficit equity 
                   
Balance at January 1, 2017    $   1,214,845  $   9,294,463  $1  $35,949  $(25,921) $10,029 
Issuance of shares        366,283      1,098,849      6,474      6,474 
Balance at January 1, 2018  1,581,128  $-   10,493,233  $1  $44,643  $(39,121) $5,523 
Issuance of common shares upon initial public offering, net of offering costs of $2,546  -   -   3,500,000   1   14,953   -   14,954 
Conversion of preferred shares to commons shares in connection with initial public offering  (1,581,128)  -   1,581,128   -   -   -   - 
Issuance of common shares upon exercise of overallotments  -   -   56,000   -   258   -   258 
Issuance of common shares upon cashless exercise of options  -   -   394   -   -   -   - 
Share based compensation  -   -   15,000   -   602   -   602 
Warrant expense  -   -   -   -   3,156   -   3,156 
Net loss  -   -   -   -   -   (7,323)  (7,323)
Balance at March 31, 2018  -   -   15,645,755   2   63,612   (46,444)  17,170 
Share based compensation              90,000      653      653   -   -   -   -   498   -   498 
Net loss                       (2,781)  (2,781)  -   -   -   -   -   (4,197)  (4,197)
Balance at March 31, 2017        1,581,128      10,483,312   1   43,076   (28,702)  14,375 
Balance at June 30, 2018  -   -   15,645,755   2   64,110   (50,641)  13,471 
Issuance of common shares upon exercise of options              754                       14,396       48       48 
Share based compensation              5,000      (56)     (56)  -   -   30,000   -   1,093   -   1,093 
Net loss                       (3,480)  (3,480)  -   -   -   -   -   (5,170)  (5,170)
Balance at June 30, 2017        1,581,128      10,489,066   1   43,020   (32,182)  10,839 
Share based compensation              2,778      1,297      1,297 
Net loss                       (3,166)  (3,166)
Balance at September 30, 2017    $   1,581,128  $   10,491,844  $1  $44,317  $(35,348) $8,970 
Balance at September 30, 2018  -  $-   15,690,151  $2  $65,251  $(55,811) $9,442 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


Motus GI Holdings, IncInc.

Condensed Consolidated Statements of Cash Flows

(In thousands, except share and per share amounts)

(unaudited)

      For the Nine Months Ended September 30, 
 For the Nine Months Ended September 30,  2019 2018 
 2018  2017 
     
��     
CASH FLOWS FROM OPERATING ACTIVITIES:             
Net loss $(16,690) $(9,427) $(17,149) $(16,690)
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization  106   42   157   106 
Revaluation of contingent royalty obligation  244   206 
(Gain) loss on change in estimated fair value of contingent royalty obligation  (68)  244 
Share based compensation  1,735   1,894   2,530   1,735 
Unrealized gain on investments  (5)  - 
Amortization of bond premium  15      -   15 
Inventory write-down  76   574 
Fixed asset impairment  35   - 
Non-cash operating lease expense  185   - 
Warrant expense  3,156      -   3,156 
Inventory write-down  574    
Changes in operating assets and liabilities:                
Accounts receivable  (18)  (1)  5   (18)
Inventory  (614)  (376)  (732)  (614)
Prepaid expenses and other current assets  (74)  (126)  (43)  (74)
Other long-term assets     (255)
Accounts payable and accrued expenses  1,141   364   593   1,141 
Other current and long-term liabilities  (108)  61 
Operating lease liabilities - current and non-current  (182)  - 
Other current and non-current liabilities  203   (108)
Net cash used in operating activities  (10,533)  (7,618)  (14,395)  (10,533)
                
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchase of fixed assets  (194)  (656)  (361)  (194)
Proceeds from (repayment of) long-term deposits  11   (24)
Proceeds from long-term deposits  -   11 
Repayment of shareholder loan receivable  126      -   126 
Purchase of held-to-maturity securities  -   (4,863)
Purchase of available-for-sale securities  (5,026)     (9,609)  (5,026)
Proceeds from sale of available-for-sale securities  2,000      2,000   2,000 
Purchase of held-to-maturity securities  (4,863)   
Proceeds from maturity of held-to-maturity securities  3,130      -   3,130 
        
Net cash used in investing activities  (4,816)  (680)  (7,970)  (4,816)
                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from public offering, net of broker commissions of $1,400  16,100    
Payments of public offering costs  (1,109)   
Proceeds from exercise of options, net of broker commissions of $22  306    
Proceeds from issuance of shares, net of financing cost of $851     6,474 
Gross proceeds from public offering  20,000   17,500 
Proceeds from exercise of over-allotment options  1,945   - 
Proceeds from exercise of options  2   306 
Financing fees  (1,915)  (2,509)
Net cash provided by financing activities  15,297   6,474   20,032   15,297 
                
NET DECREASE IN CASH AND CASH EQUIVALENTS  (52)  (1,824)  (2,333)  (52)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  6,939   11,651   18,050   6,939 
CASH AND CASH EQUIVALENTS AT END OF PERIOD $6,887  $9,827  $15,717  $6,887 
                
SUPPLEMENTAL CASH FLOW INFORMATION:                
CASH PAID FOR:                
Interest $  $  $-  $- 
Income taxes $  $  $-  $- 
                
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:                
Reclassification of deferred financing fees from current assets to common stock $602  $ 
Reclassification of deferred financing costs from current assets to additional paid-in capital $-  $602 
Cashless exercise of options $2  $  $-  $2 

Deferred financing fees included in accounts payable and accrued expenses

 

$

59  $  $-  $59 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

 

Note 1 - Description of Business

 

Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus, Ltd. and Motus, Inc., are collectively referred to as “Motus GI” or the “Company”.

 

The Company has developed the Pure-Vu System (the “Pure-Vu System”), a single-use medical device system,that has received 510(k) clearance from the Pure-Vu system, cleared by the United StatesU.S. Food and Drug Administration (the “FDA”). In June 2019, the 510(k) premarket notification for the second-generation of the Pure-Vu System was reviewed and whichcleared by the FDA. The first-generation of the Pure-Vu System has received CE Mark approval in the European Economic Area, thatand the Company intends to seek CE Mark approval for the second-generation of its Pure-Vu System. The Pure-Vu System is intended to attach to standard colonoscopesindicated to help facilitate intraproceduralthe cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter. The Company began commercialization in October 2019, with the first commercial placements of its second generation Pure-Vu system has been designed to integrate with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care for a hospital in a market segment where most of the reimbursement is under a bundle payment based on a DRG (Diagnostic Related Group). The Pure-Vu system does not currently have a unique reimbursement code with any private or governmental third-party payors in any country. To date,System as part of the Company’s limitedits initial U.S. market development launch the Company has focused on collecting additional clinical and health economic data, as exemplified by the recently initiated Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement Study (the “REDUCE Study”), along with garnering valuable experience in key hospitals on the use of the Pure-Vu system to support a full launch in the United States inpatient market in 2019.targeting early adopter hospitals. The Company does not expect to generate significant revenue from product sales unless and until the Company expands its commercialization efforts.efforts for the Pure-Vu System, which is subject to significant uncertainty.

 

Note 2 – Basis of Presentation and Going Concern

 

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 20172018 10-K filed with the SEC on March 28, 2018.26, 2019. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 20172018 balance sheet information was derived from the audited financial statements as of that date. Certain reclassifications to prepaid expenses and other current assets, and other current and long-term liabilities, other expenses, and income tax expense have been made to the prior period condensed consolidated financial statements to conform to the current period presentation.

 

To date, the Company has generated minimal revenues, experienced negative cash flows and has incurred substantial operating losses from its activities. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources, future product sales, and through additional raises of capital.

 

The Company has financed its operations primarily through sales of equity-related securities. At September 30, 2018,2019, the Company had an accumulated deficit of approximately $55.8 million,$78,527, total current assets of approximately $12.9 million$27,682 and total current liabilities of approximately $2.5 million$3,547 resulting in working capital of approximately $10.4 million.$24,135. For the three and nine months ended September 30, 2019, the Company incurred a net loss of $5,195 and $17,149, respectively. At September 30, 2018,2019, the Company had cash and cash equivalents, and short-term investments of approximately $11.6 million. Based on the Company’s current business plan, it believes their cash, cash equivalents, and short-term investments balance as of September 30, 2018 will be sufficient to meet its anticipated cash requirements through approximately the second quarter of 2019. However, there is no assurance that the current business plan will be achievable.$26,374.

 

Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes revenue generation through the sale of products and raising funds from outside investors. However, there is no assurance that such sale of products will occur or that outside funding will be available to the Company, will be obtained on favorable terms or will provide the Company with sufficient capital to meet its objectives. These condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

 

Note 3 – Summary of Significant Accounting Policies

 

A summary of the significant accounting policies applied in the preparation of the accompanying condensed consolidated financial statements follows:

 

PrinciplesBasis of Consolidationpresentation and principles of consolidation

 

The accompanying unaudited condensed consolidated financial statements represent the consolidation ofhave been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in conformity with GAAP.Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All intercompanyinter-company accounts and transactions have been eliminated in consolidation.

 

Use of estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Functional currency and foreign currency translation

The functional currency of the Company, inclusive of foreign subsidiaries, is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the unaudited condensed consolidated statement of comprehensive loss as foreign currency (loss) gain, as appropriate.

Cash and Cash Equivalentscash equivalents

 

The Company considers all highly liquid investment securities with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Cash and cash equivalents include cash on-hand and highly-rated U.S. government backed money market fund investments.

 

Short-term Investments

 

The Company invests all excess cash primarilyaccounts for investments held as “available-for-sale” in debt securities.

Investment securities that managementaccordance with ASC 320, “Investments - Debt and Equity Securities”. The Company has the positive intentone investment in a mutual fund and ability to hold to maturityclassifies this investment as a current asset and carries it at fair value. Unrealized gains and losses are classified as held-to-maturity securities and are carried at amortized cost. Purchase premiums and discounts are recognizedrecorded in finance income, net overon the termcondensed consolidated statement of the security. Investment securities not classified as held-to-maturity securitiescomprehensive loss. Realized gains or losses on mutual fund transactions are classified as available-for-sale securities and recorded at fair value, with unrealized gains and losses reported in netthe condensed consolidated statement of comprehensive loss. Gains and losses on the sale of available-for-sale securities are recorded on the trade date.The mutual fund is maintained at one financial institution.

 

Management evaluates whether available-for-sale securities and held-to-maturity securities are other-than-temporarily impaired (OTTI)(“OTTI”) on a quarterly basis. Debt securities with unrealized losses are considered OTTI if the Company intends to sell the security or if it is more likely than not that the Company will be required to sell such security prior to any anticipated recovery. If management determines that a security is OTTI, under these circumstances, the impairment recognized in earnings is measured as the entire difference between the amortized cost and the then-current fair value. During the three and nine months ended September 30, 2019 and 2018, no investment OTTI losses were realized.

 

The Company’s investment policy is focused on the preservation of capital, liquidity and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price.

 

7

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

Revenue Recognitionrecognition

 

The FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted this ASU effective January 1, 2018 on a full retrospective basis. Adoption of this standard did not result in significant changes to accounting policies, business processes, systems or controls, or have a material impact on the financial position, results of operations and cash flows or related disclosures. As such, prior period financial statements were not recast.

first generationThe Pure-Vu System – The Company manufacturesdeveloped a first generation medical device system (a “Workstation”) and a single use disposable sleeve (a “Disposable”) designed to improve a colonoscopy procedure. These productsIn market development accounts, the Company places its Workstations in a healthcare professional’s office at no charge. The Disposables are shipped directly to healthcare professionals under contract-based terms. Revenueused in conjunction with the Workstation. The Company typically enters into agreements for an evaluation period that have terms of two and three months and can be extended for successive periods by written agreement by both the products sold is recognized atCompany and the point in time when control transfers tocustomer. The Company initially provides the customer which is generally whenwith a free demonstration pack of Disposables so that the shipment is receivedcustomer can evaluate both the Workstation and accepted byDisposables. After the customer. In certain circumstances, products are available for free of charge for a limited evaluation period. At the end of the limited evaluation period, the customerCompany may purchasecharge a fee for the products atfirst generation Disposables shipped once the free demonstration pack is used. The Company recognizes revenue for the fees charged over the term of the arrangement, which timeequates to usage.

For the purposes of GAAP only, this type of arrangement for the first generation system is treated as a short-term operating lease, and thus is outside the scope of ASC 606 and is accounted for in accordance with ASC 842, Leases. Effective January 1, 2019, there was no material impact upon the adoption of ASC 842 related to these arrangements. While this arrangement is not an operating lease contractually, this arrangement is viewed as an operating lease for accounting purposes since in this arrangement the Company will recordprovides the correspondingcustomer the rights to use the Workstation and Disposables, which are interdependent, and the customer controls physical access to the Workstation while controlling the utility and output during the term of the arrangement.

During the three and nine months ended September 30, 2019, the Company recognized revenue orof $3 and $8, respectively, and, during the products may be returned. As ofthree and nine months ended September 30, 2018, the Company had no future performance obligationsrecognized revenue of $0 and $38, respectively, from any customer contracts.the sale of first generation Disposables which equates to the usage period of the Disposables over the term of the agreement.

 

Accounts receivable and allowance for doubtful accounts

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. The Company makes estimates for the allowance for doubtful accounts based upon its assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect customers’ ability to pay. As of September 30, 2019 and December 31, 2018, the allowance for doubtful accounts was $0.

Inventory

Inventory is stated at lower of cost or net realizable value using the weighted average cost method and is evaluated at least annually for impairment. Write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts. For the three and nine months ended September 30, 2019, an inventory write-down charge of $57 and $76, respectively, was recorded; and, for both the three and nine months ended September 30, 2018, an inventory write-down charge of $574 was recorded.

Inventory at September 30, 2019 and December 31, 2018 consisted of the following:

  September 30,
2019
  December 31,
2018
 
Raw materials $238  $- 
Work-in-process  160   - 
Finished goods  373   23 
Ending inventory $771  $23 

8

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

Leases

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. On January 1, 2019, the Company adopted the new lease standard using the optional transition method under which comparative financial information will not be restated and continue to apply the provisions of the previous lease standard in its annual disclosures for the comparative periods. In addition, the new lease standard provides a number of optional practical expedients in transition. The Company elected the package of practical expedients. As such, the Company did not have to reassess whether expired or existing contracts are or contain a lease; did not have to reassess the lease classifications or reassess the initial direct costs associated with expired or existing leases.

The new lease standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption under which the Company will not recognize right-of-use (“ROU”) assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases. The Company elected the practical expedient to not separate lease and non-lease components for certain classes of assets (facilities).

On January 1, 2019, the Company recognized ROU assets of $1,065 and lease liabilities of $1,074 and no adjustment was made to the Company’s accumulated deficit. The adoption of the new lease standard did not impact the Company’s condensed consolidated statement of comprehensive loss or its condensed consolidated statement of cash flows.

The Company determines if an arrangement is a lease at inception. For the Company’s operating leases, the ROU asset represents the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Since all of the lease agreements do not provide an implicit rate, the Company estimated an incremental borrowing rate in determining the present value of the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as operating costs and property taxes are expensed as incurred.

Fixed assets, net

Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method, at annual rates reflecting the estimated useful lives of the related assets, as follows:

Office equipment5-15 years
Computers and software3-5 years
Machinery5-10 years
Lab and medical equipment3-7 years
Leasehold improvementsShorter of lease term or useful life

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

 

Fixed assets, summarized by major category, consist of the following for the years ended:

  September 30,
2019
  December 31,
2018
 
Office equipment $148  $144 
Computers and software  320   284 
Machinery  460   329 
Lab and medical equipment  471   391 
Leasehold improvements  180   105 
Total  1,579   1,253 
Less: accumulated depreciation and amortization  (564)  (407)
Fixed assets, net $1,015  $846 

Depreciation and amortization expense for the three and nine months ended September 30, 2019 is $58 and $157, respectively. Depreciation and amortization expense for the three and nine months ended September 30, 2018 is $44 and $106, respectively. For the three and nine months ended September 30, 2019, a fixed asset impairment charge of $35 was recorded as general and administrative expense to write down lab and medical equipment related to the first-generation Pure-Vu System.

Stock Based Compensation

2016 Equity Incentive Plan

In December 2016, the Company adopted the Motus GI Holdings, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). Pursuant to the 2016 Plan, the Company’s board of directors may grant options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock, stock units, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards to employees, officers, directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2016 Plan, the number of shares of common stock available for issuance under the 2016 Plan shall increase annually by six percent (6%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year; provided, however, that the board of directors may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of our common stock than would otherwise occur. On January 1, 2019, pursuant to an annual evergreen provision, the number of shares of common stock reserved for future grants was increased by 1,286,409 shares. Under the 2016 Plan, the maximum number of shares of the Company’s common stock authorized for issuance is 3,927,659. As of September 30, 2019, there were 92,202 shares of common stock available for future grant under the 2016 Plan.

Adoption of Accounting Standards Update 2018-07

The Company has adopted Accounting Standards Update 2018-07 (“ASU 2018-07”), “Improvement to Nonemployee Share-based Payment Accounting”, which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new guidance will be applied prospectively to all new awards granted after the date of adoption. In addition, the new guidance will be applied to all existing equity-classified awards for which a measurement date has not been established under ASC 505-50 by the adoption date by remeasuring at fair value as of the adoption date, and recording a cumulative effect adjustment to opening accumulated deficit on January 1, 2019.

For the Company’s equity-classified awards for which a measurement date has not been established under ASC 505-50, the fair value on January 1, 2019, the adoption date, approximated the value assigned on December 31, 2018, therefore no cumulative adjustment to opening accumulated deficit was required.

10

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

Under the revised guidance, the accounting for awards issued to non-employees will be similar to the model for employee awards, except that ASU 2018-07:

allows the Company to elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and

the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.

Employee and Non-Employee Stock Based Compensation

 

The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.

 

ASC 718-10 requires companies to estimate the fair value of equity-based paymentoption awards on the date of grant using an option-pricing model. The fair value of the portion of the award that is ultimately expected to vest is recognized as an expense on a straight-line basis over the requisite service periods in the Company’s condensed consolidated statement of operations.comprehensive loss. The Company recognizes share-based award forfeitures as they occur rather than estimate by applying a forfeiture rate. 

The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees” (“FASB ASC 505-50”). Under FASB ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Non-employee equity based payments are recorded as an expense over the service period, as if the Company had paid cash for the services. At the end of each financial reporting period, prior to vesting or prior to the completion of the services, the fair value of the equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity based payments are fully vested or the service completed.

The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award.occur.

 

The Company estimates the fair value of stock options granted asoption equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.

 

Restricted Stock Units

The Company issues restricted stock units under its 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.

Basic and diluted net loss per share

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive ordinary shares had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”. Potentially dilutive common shares were excluded from the calculation of diluted loss per share for all periods presented due to their anti-dilutive effect due to losses in each period.

Research and development expenses, net

Research and development expenses are charged to the unaudited condensed consolidated statement of comprehensive loss as incurred.

11

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

Patent costs

Costs incurred in connection with acquiring patent rights and the protection of proprietary technologies are expensed as incurred.

Liabilities due to termination of employment agreements

Under Israeli employment laws, employees of Motus Ltd. are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Motus Ltd. on their behalf with insurance companies.

Payments in accordance with Article 14 release Motus Ltd. from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.

Income Taxestaxes

 

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2018,2019 and December 31, 2017,2018, the Company had a full valuation allowance against deferred tax assets.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

The Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017, among other things, permanently lowered the statutory federal corporate tax rate from 35% to 21%, effective for tax years including or beginning January 1, 2018. Under the guidance of ASC 740, “Income Taxes” (“ASC 740”), the Company revalued its net deferred tax assets on the date of enactment based on the reduction in the overall future tax benefit expected to be realized at the lower tax rate implemented by the new legislation. Although in the normal course of business the Company is required to make estimates and assumptions for certain tax items which cannot be fully determined at period end, the Company did not identify items for which the income tax effects of the Tax Act have not been completed as of September 30, 2018 and, therefore, considers its accounting for the tax effects of the Tax Act on its deferred tax assets and liabilities to be complete as of September 30, 2018.assets.

 

For the three and nine months ended September 30, 20182019 and 2017,2018, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and nine months ended September 30, 20182019 and 2017,2018, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.

 

Fair Value Measurementsvalue of financial instruments

 

The Company accounts for financial instruments in accordance with ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not active or financial instruments for which all significant inputsdirectly observable but are corroborated by observable either directly or indirectly; andmarket data;

 

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

 

There were no changes in the fair value hierarchy leveling during the three and nine months ended September 30, 2019 and during the year ended December 31, 2018.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

 

The following table summarizes the fair value of our financial assets and liabilities that were accounted for at fair value on a recurring basis, by level within the fair value hierarchy, as of September 30, 20182019 and December 31, 2017:2018:

 

 September 30, 2018  September 30, 2019 
 Level 1 Level 2 Level 3 Fair Value  Level 1  Level 2  Level 3  Fair Value 
Assets                  
Short-term investments $3,026  $  $  $3,026 
Total $3,026  $  $  $3,026 
Investments $10,657  $-  $-  $10,657 
                                
Liabilities                                
Contingent royalty obligation $  $  $1,906  $1,906  $-  $-  $1,885  $1,885 
Total $  $  $1,906  $1,906 

 

  December 31, 2017 
  Level 1  Level 2  Level 3  Fair Value 
Liabilities            
Contingent royalty obligation $  $  $1,662  $1,662 
Total $  $  $1,662  $1,662 


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

  December 31, 2018 
  Level 1  Level 2  Level 3  Fair Value 
Assets            
Investments $3,043  $-  $-  $3,043 
                 
Liabilities                
Contingent royalty obligation $-  $-  $1,953  $1,953 

 

Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature.

 

Contingent Royalty Obligation

 

In estimating the fair value of the Company’s contingent royalty obligation (see Note 5)6), the Company used the discounted cash flow method as of September 30, 20182019 and December 31, 2017.2018. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because valuation inputs are based on projected revenues discounted to a present value.

 

The following table sets forth a summary of changes in the estimated fair value of the Company’s Level 3 contingent royalty obligation for the nine months ended September 30, 2018:2019:

 

  Fair Value Measurements of Contingent Royalty Obligation (Level 3) 
Balance at January 1, 2018 $1,662 
Change in estimated fair value of contingent royalty obligation  244 
Balance at September 30, 2018 $1,906 
  Fair Value Measurements of Contingent Royalty Obligation (Level 3) 
Balance at December 31, 2018 $1,953 
Change in estimated fair value of contingent royalty obligation  (68)
Balance at September 30, 2019 $1,885 

 

The contingent royalty obligation is re-measured at each balance sheet date using the following assumptionsassumptions: 1) discount rate of 21% and 20% as of September 30, 20182019 and December 31, 2017: 1) Discount rate of 20%,2018, respectively, and 2) rate of royalty payment of 3%. as of both September 30, 2019 and December 31, 2018.

 

For the nine months ended September 30, 2019, the Company’s estimated discount rate increased from 20% to 21% due to changes in market conditions.

In accordance with ASC-820-10-50-2(g), the Company performed a sensitivity analysis of the liability, which was classified as a Level 3 financial instrument. The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by approximately $211$175 and a 2% increase in the discount rate would decrease the liability by approximately $186.

Recently Issued Accounting Standards

In February 2016, the FASB issued ASU 2016-02 “Leases” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. For operating leases, the ASU requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The ASU retains the current accounting for lessors and does not make significant changes to the recognition, measurement, and presentation of expenses and cash flows by a lessee. The ASU is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company is in the process of implementing changes to its systems and processes in conjunction with its review of lease agreements. The Company will adopt ASU 2016-02 effective January 1, 2019 and expects to elect certain available transitional practical expedients.

$157.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

Recently issued accounting standards

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. The ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. TheIn April 2019 and May 2019, the FASB issued ASU is effective forNo. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the Company inpreviously issued ASU. Management has not yet completed its assessment of the first quarterimpact of 2020, with early adoption permitted.the new standards on the Company’s financial statements. The Company is currently evaluating the effect the adoption of this ASUthese ASUs will have on its consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting,” which clarifies when a change to terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the vesting condition, fair value or the award classification is not the same both before and after a change to the terms and conditions of the award. The new guidance was adopted by the Company on January 1, 2018, on a prospective basis. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

In June 2018, These ASUs are effective for the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”, which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard will be effectiveCompany in the first quarter 2019, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company is currently evaluating the effect the adoption of this ASU will have on its consolidated financial statements.2020.

 

In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standardASU 2018-13 removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.the Company in the first quarter of 2020. The Company will beis evaluating the impact this standard will have on the Company’s condensed consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-15, “Internal-Use Software (Subtopic 350-40)—Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service”. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license), by requiring a customer in a cloud computing arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. ASU 2018-15 will be effective on January 1, 2020. The Company is currently evaluating the impact of this new standard.

Note 4 – Short-term investmentsInvestments

 

Short term investmentsInvestments as of September 30, 2019 and December 31, 2018 consist of held-to-maturity securities which are carried at amortized costs and available-for-sale securities which are carried at fair value. Interest and dividends on short-term investments are included in finance income, net. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in finance income, net. The Company did not have any short-term investments at December 31, 2017.

 

The following table summarizes, by major security type, the Company’s short-term investments as of September 30, 2018.2019 and December 31, 2018:

 

  Amortized Cost  Carrying Value 
Mutual fund, available for sale $3,026  $3,026 
Corporate debt securities, held-to-maturity  1,718   1,718 
Total $4,744  $4,744 
  September 30, 2019 
  Amortized Cost  Carrying Value 
Mutual fund, available-for-sale $10,652  $10,657 
Total $10,652  $10,657 

  December 31, 2018 
  Amortized Cost  Carrying Value 
Mutual fund, available-for-sale $3,043  $3,043 
Total $3,043  $3,043 

Note 5 – Leases

 

The Company had deminimus unrealized gains and losses from available-for-sale securities during the three and nine months ended September 30, 2018. Actual maturities may differ from contractual maturities because the issuers may have the rightleases an office in Fort Lauderdale, Florida under an operating lease. The term expires November 2024. The annual base rent is subject to call or prepay obligations with or without call or prepayment penalties. Contractual securities mature from October 2018 through November 2018.

annual increases of 2.75%.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

The Company leases an office in Israel under an operating lease that expires on December 31, 2019. On July 4, 2019, the Company exercised its option to extend the lease expiration to December 31, 2022. The right-of-use asset and lease liability were adjusted to include the renewal period in the amount of $176. The base rent is subject to a 4% increase beginning on January 1, 2020.

The Company leases vehicles under operating leases that expire at various dates through 2022.

Many of these leases provide for payment by the Company, as the lessee, of taxes, insurance premiums, costs of maintenance and other costs which are expenses as incurred. Certain operating leases include escalation clauses and some of which may include options to extend the leases for up to 3 years.

Operating cash flow supplemental information for the nine months ended September 30, 2019:

An initial right-of-use asset of $1,065 was recognized as a non-cash asset and operating lease liabilities of $1,074 was recognized as a non-cash liability addition with the adoption of the new lease standard. An initial right-of-use asset and liability in the amount of $176 was recognized as a non-cash asset and operating lease liability upon the exercise of its option to extend the Israel lease. Cash paid for amounts included in the present value of operating lease liabilities was $261 during the nine months ended September 30, 2019.

Other Information:
Weighted average remaining lease term – operating leases, in years4.31
Weighted average discount rate – operating leases7.69%

Future minimum lease payments under non-cancellable operating leases as of September 30, 2019 were as follows:

Twelve Months Ended December 31, Amount 
2019 (remaining three months) $86 
2020  319 
2021  266 
2022  253 
2023  184 
Thereafter  141 
Total future minimum lease payments  1,249 
Imputed interest  (181)
Total liability $1,068 

The Company’s lease expense was $127 and $356 for the three and nine months ended September 30, 2019, respectively, included in general and administrative expenses. The Company’s lease expense was $122 and $368 for the three and nine months ended September 30, 2018, respectively, included in general and administrative expenses.

 

Note 56 – Commitments and Contingencies

 

Royalty on Coated Products

 

On January 30, 2018, the Company entered into a license and supply agreement with a third party whereby it was granted a worldwide license to sell its products coated with an agent that is the intellectual property of the third party for providing a lubricious surface to the Company’s products (a “Coated Product” or “Coated Products”). The third party is entitled to a royalty in the amount of:

 

a.2% of the first $25 million in annual net sales of Coated Products; and

b.1.5% once annual net sales exceed $25 million of Coated Products.

 

The above two tiers reset annually on January 1st of each calendar year.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

 

Minimum royalties shall be paid for each Coated Product sold by the Company as follows:

 

a.January 1, 2020 to December 31, 2020 - $5 per calendar quarter;

b.January 1, 2021 to December 31, 2021 - $10 per calendar quarter;

c.January 1, 2022 and beyond - $15 per calendar quarter.

 

Additionally, the Company shall make one-time milestone payments as follows:

 

a.$12.5 due 6 months after the first commercial sale of a Coated Product.

b.$12.5 due 12 months after the first commercial sale of a Coated Product.

c.$25 due 18 months after the first commercial sale of a Coated Product.

 

The Company provided the third party a notice of termination of the license and supply agreement, which is effective ninety days from September 30, 2019. The Company shipped its first commercial Coated Product in the second quarter of 2019. For the three and nine months ended September 30, 2019, the Company has recorded a de minimus amount in relation to the royalty on coated products as cost of revenue. For the three and nine months ended September 30, 2019, the Company recorded $37 as a reduction to general and administrative expense for the reversal of the estimated accrual for additional one-time milestone payments. As of September 30, 2019, the Company has recorded $13 as other current liabilities to accrue the one-time milestone payment.

For the three and nine months ended September 30, 2018, the Company has recorded $0 and $50, respectively, as general and administrative expense to accrue the one-time milestone payments in anticipation of the first commercial sale of a coated product in the next six months.product. As of September 30,December 31, 2018, the Company has recorded $13$25 as other current liabilities and $37$25 as long-term liabilities. After discussions withother non-current liabilities to accrue the vendor, previous shipments have been deemed for pilot use and not a commercial sale.one-time milestone payments.

 

Royalties to the IIA

 

The Company has received grants from the Government of the State of Israel through the IsraelIsraeli National Authority for Technical Innovation Authority of the Ministry of Economy and Industry (the “IIA”) (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry (the “OCS”)) for the financing of a portion of its research and development expenditures pursuant to the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research and Development Law, 5744-1984), referred to as the Research Law, and related regulations.expenditures. The Company has received funding from the IIA, whichtotal amount that was received and recorded between the periods ending December 31, 2011 through 2016 inwas $1,332. The total amount received during the aggregate amount of $1,332three and nine months ended September 30, 2019 and 2018 was $0. The Company has a contingent obligation to the IIA for the total amount received along with the accumulated LIBOR interest to date in the amount of approximately $1,382$1,394 and $1,383 as of September 30, 2019 and December 31, 2018, whichrespectively. This obligation is generally repaid in the form of royalties ranging from 3%on revenues generated in any fashion with a rate that is currently at 4% (which may be increased under certain circumstances). The Company may be obligated to 5% of revenues on sales of products and services based on technology developed using IIA grants,pay up to an aggregate of 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grant,grants received, plus interest at the rate of 12-month LIBOR.

 

Repayment of the grants is contingent upon the successful completion of the Company’s R&D programs and generating sales. The Company has no obligation to repay these grants if the R&D program fails, is unsuccessful, or aborted, or if no sales are generated. The Company has recorded $0 and an immaterial expense and liability during the three and nine months ended September 30, 2019 and 2018 respectively, as sales occur.

 


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

Royalty Payment Rights on Royalty Payment Rights Certificates

 

The Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”), establishing the rights and preferences of the holders of the Series A Convertible Preferred Stock, (“including certain directors and officers of the RoyaltyCompany (the “Royalty Payment Rights”). As set forth in the in the Certificate of Designation, the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of:

 

3% of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and

5% of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement.

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

 

In addition, in connection with completion of the 2017 private placement,Private Placement, the Company issued the placement agent royalty payment rights certificates (the “Placement Agent Royalty Payment Rights Certificates”) which grants the placement agent, and its designees, the right to receive, in the aggregate, 10% of the amount of payments paid to the holders of the Series A Convertible Preferred Stock, or the holders of the Royalty Payment Rights Certificates (the “Royalty Payment Rights Certificates”), upon the conversion of the Series A Convertible Preferred Stock into shares of the Company’s common stock. The Placement Agent Royalty Payment Rights Certificates are on substantially similar terms as the Royalty Payment Rights of the Series A Convertible Preferred Stock.

 

The Royalty Payment Rights Certificate obligation and Placement Agent Royalty Payment Rights Certificate obligation (the “Contingent Royalty Obligation”) was recorded as a liability at fair value as “Contingent royalty obligation” in the condensed consolidated balance sheets at September 30, 20182019 and December 31, 20172018 (see Contingent Royalty Obligation below). The fair value at inception was allocated to the royalty rights and the residual value was allocated to the preferred shares and recorded as equity.

 

The Company amended its Certificate of Designation to modify the Royalty Payment Rights when the Company consummated its Initial Public Offering (“IPO)IPO”) on February 16, 2018, at which time the Company converted the Series A Convertible Preferred Stock into shares of the Company’s common stock and issued the Royalty Payment Rights Certificates. Pursuant to the terms of the Royalty Payment Rights Certificates, if and when the Company generates sales of the current and potential future versions of the Pure-Vu system,System, including disposables, parts, and services, or if the Company receives any proceeds from the licensing of the current and potential future versions of the Pure-Vu system,System, then the Company will pay to the holders of the Royalty Payment Rights Certificates a royalty (the “Royalty Amount”) equal to, in the aggregate, in royalty payments in any calendar year for all products:

 

3% of net sales*Net Sales* for commercialized product directly; and

5% of any licensing proceeds*Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party.

 

* Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a cap per calendar year of $30,000. Net Sales is defined in the Certificate of Designations. The Company has not reached the Initial Net Sales Milestone as of September 30, 2018.

*Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Net Sales” is defined in the Royalty Payment Rights Certificates. The Company has not reached the Initial Net Sales Milestone as of September 30, 2019.

 

** Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $3,500 (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a cap per calendar year of $30,000. Licensing Proceeds is defined in the Certificate of Designations. The Company has not reached the Initial Licensing Proceeds Milestone as of September 30, 2018.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

**Notwithstanding the foregoing, with respect to Licensing Proceeds based Royalty Amounts, (a) no Licensing Proceeds based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Licensing Proceeds equal to $3,500 (the “Initial Licensing Proceeds Milestone”), and royalties shall only be computed on, and due with respect to, Licensing Proceeds in excess of the Initial Licensing Proceeds Milestone and (b) the total Licensing Proceeds based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Licensing” Proceeds is defined in the Royalty Payment Rights Certificate. The Company has not reached the Initial Licensing Proceeds Milestone as of September 30, 2019.

 

The Royalty Amount will be payable up to the later of (i) the latest expiration date forof the Company’s current patents (which is currently November 2034),issued as of December 22, 2016, or (ii) the latest expiration date of any pending patents as of the date of the initial closing of the 2017 Private PlacementDecember 22, 2016 that have since been issued or may be issued in the future.future (which is currently April 2035). Following the expiration of all such patents, the holders of the Royalty Payment Rights Certificates and the holders of the Placement Agent Royalty Payment Rights Certificates will no longer be entitled to any further royalties for any period following the latest to occur of such patent expiration.

 

On February 16, 2018, the date of the closing of the IPO, (1) the amendment to the Certificate of Designation became effective, (2) all outstanding shares of Series A Convertible Preferred Stock were converted into shares of the Company’s common stock pursuant to a mandatory conversion, and (3) the Royalty Payment Rights Certificates were issued to the former holders of the Series A Convertible Preferred Stock. As provided for in the Certificate of Designation, if a holder had elected to convert a portion or all their Series A Convertible Preferred Stock into shares of the Company’s common stock prior


Motus GI Holdings, Inc. and Subsidiaries

Notes to the mandatory conversion, the holder would have forfeited all rights to future royalty payments, if any. No such conversion elections were received by the Company prior to the mandatory conversion.Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

 

Contingent Royalty Obligation

 

The Contingent Royalty Obligation was recorded as a long-termnon-current liability at fair value in the condensed consolidated balance sheets at September 30, 20182019 and December 31, 20172018 in the amount of $1,906$1,885 and $1,662,$1,953, respectively. For the three and nine months endingended September 30, 20182019, the Company recorded a gain on change in fair value of Contingent Royalty Obligation in the amount of $127 and 2017,$68, respectively. For the three and nine months ended September 30, 2018, the Company recorded a loss on change in fair value of Contingent Royalty Obligation in the amount of $85 and $72, respectively. For the nine months ending September 30, 2018 and 2017, the Company recorded a loss on change in fair value of Contingent Royalty Obligation in the amount of $244, and $207, respectively.

 

Employment Agreements

Effective October 1, 2018 (the “Commencement Date”), the Company entered into an employment agreement with Timothy P. Moran as Chief Executive Officer of the Company. Mr. Moran succeeded Mark Pomeranz, in his position as Chief Executive Officer. Mr. Pomeranz continued his employment with the Company as President and Chief Operating Officer.

Employment Agreement with Mr. Moran

The Company entered into an employment agreement with Mr. Moran (the “CEO Employment Agreement”), which became effective on October 1, 2018, on an at-will basis, which contains non-disclosure and invention assignment provisions. Under the terms of Mr. Moran’s employment agreement, he will hold the position of Chief Executive Officer and receive a base salary of $475 annually (the “Base Salary”). In addition, Mr. Moran is eligible to receive an annual bonus payment (the “Performance Bonus”) in an amount equal to up to sixty percent (60%) of his then-Base Salary (the “Bonus Target”) if the Board determines that he has met the target objectives communicated to him. For the first twelve months of his employment (the period from October 1, 2018 through October 1, 2019), the payout range for the Performance Bonus shall be between fifty percent (50%) and two hundred percent (200%) of the Bonus Target if the Board determines the objectives have been achieved. Thereafter, subsequent payout parameters will be determined by the Board based upon parameters set by the Board and Mr. Moran for an overall Company executive bonus program using market data and analysis input from a third-party expert compensation firm.

In connection with his employment agreement, within 30 days after the Commencement Date, Mr. Moran will be granted (i) an option to purchase 495,000 shares (the “Initial Option Grant”) of the Company’s common stock (the “Common Stock”) pursuant to the Company’s 2016 Equity Incentive Plan (the “Plan”), at an exercise price equal to the “Fair Market Value” of a share of Common Stock on the “Date Of Grant” (as such terms are defined by the Plan) and (ii) a restricted stock unit award for 165,000 shares of Common Stock pursuant to the Plan (the “Initial Restricted Stock Unit Award”). The Initial Option Grant and Initial Restricted Stock Unit Award will, subject to Mr. Moran’s continued employment by the Company, vest in substantially equal quarterly installments over four years commencing from the Commencement Date. The stock option grant agreement and restricted stock unit award agreement will include terms and conditions set forth in the Company’s standard forms of such agreements under the Plan. In addition, pursuant to the terms of his employment agreement, Mr. Moran is eligible to receive, from time to time, equity awards under the Plan, or any other equity incentive plan the Company may adopt in the future, and the terms and conditions of such awards, if any, will be determined by the Board or Compensation Committee, in their discretion. Mr. Moran is also eligible to participate in any executive benefit plan or program the Company adopts. Further, Mr. Moran will be eligible to receive employment buy-out payments (the “Employment Buy-Out Payments”) in the amount of $400 each on March 1, 2019, November 1, 2019, March 1, 2020 and November 1, 2020, provided he remains actively employed, or pursuant to certain termination conditions, on each such date.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

Concurrently with the CEO Employment Agreement, the Company entered into an indemnification agreement with Mr. Moran, in the form previously entered into by the Company with each of the Company’s directors and executive officers.

Amended and Restated Employment Agreement with Mr. Pomeranz

On September 24, 2018, the Company entered into an amended and restated employment agreement (the “Amended and Restated Employment Agreement”) with Mark Pomeranz, pursuant to which Mr. Pomeranz transitioned from his current role as President and Chief Executive Officer, into the role of President and Chief Operating Officer.Manufacturing Component Purchase Obligations

 

The AmendedCompany utilizes two outsourcing partners to manufacture its Workstation and Restated Employment Agreement with Mr. Pomeranz became effectiveDisposable, and to perform final assembly and testing of finished products. These outsourcing partners acquire components and build product based on September 24, 2018, provides for employment on an at-will basis, and contains non-disclosure and invention assignment provisions. Under the terms of the Amended and Restated Employment Agreement, Mr. Pomeranz holds the position of President and Chief Operating Officer, and receives a base salary of $385 annually (the “Pomeranz Base Salary”). In addition, Mr. Pomeranz is eligible to receive (i) for the calendar year ending December 31, 2018, a bonus payment in an amount equal to up to thirty one and one quarter percent (31.25%) (the “2018 Bonus Target”) of his then base salary (the “2018 Bonus”) if the Board determines that he has met the target objectives communicated to him, with a payout range for the 2018 Bonus of between fifty percent (50%) and two hundred percent (200%) of the 2018 Bonus Target, and (ii) effective January 1, 2019 and thereafter an annual bonus payment (the “Pomeranz Performance Bonus”) in an amount equal to up to fifty percent (50%) of the Pomeranz Base Salary if the Board determines that he has met the target objectives communicated to him. Payout parameters for the Pomeranz Performance Bonus will be determineddemand information supplied by the Board based upon parameters set by the Board and CEO for an overall Company executive bonus program using market data and analysis input from a third-party expert compensation firm. Pursuant to the termsCompany. As of the Amended and Restated Employment Agreement, Mr. Pomeranz is also eligible to receive, from time to time, equity awards under the Company’s existing equity incentive plan, or any other equity incentive planSeptember 30, 2019, the Company may adoptexpects to pay $55 under manufacturing-related supplier arrangements within the next year, substantially all of which is noncancelable.

Other Commitments

The Company has a severance contingency for severance payments to its CEO, COO, and CFO in the future, andaggregate of approximately $1,319, in the terms and conditions of such awards, if any, will be determined by the Boardevent that they are terminated without cause or Compensation Committee,leave due to good reason, as outlined in their discretion. Mr. Pomeranzemployee agreements. Management estimates that the likelihood of payment is also eligible to participateremote; therefore, no liability was reflected in any executive benefit plan or program we adopt.these condensed consolidated financial statements.

 

Note 67 – Related Party Transactions

 

Other than transactions and balances related to cash and share-based compensation to officers and directors, the Company did not have any transactions and balances with related parties and executive officers during the three and nine months ending September 30, 2018 and 2017 except for the following:Shareholder Loan

 

Shareholder Loan

During the nine months ended September 30, 2018, theThe Company received $126 in cash proceeds as repayment ofentered into a shareholder loan. The loan was entered into on May 15, 2017 for a principal balance of $122 at a stated interest rate of 3.4%. The loan principal and accrued interest was repaid in full as of September 30, 2018. For the three and nine months ended September 30, 2018, the Company recorded $0$3 and $4, respectively, as finance income related to the shareholder loan. For the threeThe loan principal and nine months ended September 30, 2017, the Company recorded $0accrued interest was repaid in full as finance income related to the shareholder loan.of December 31, 2018.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

 

Sales and Marketing Services Arrangement with FreeHold Surgical, Inc.

 

Beginning in the fourth quarter of 2017, the Company began to make payments to FreeHold Surgical, Inc (“FreeHold”), an entity in which one of our Directors serves as a Director and President, for services rendered beginning August 2017. In the third quarter ofOn October 31, 2018, the Company gave thirty-day notice to FreeHold for termination of its services agreement was amended to reduce the number of sales representatives from two to one and revise the fee arrangement from $25 to $8 for each month. Pursuant to the fee arrangement, the Company paid FreeHold a monthly amount of approximately $25 for each month through Juneeffective November 30, 2018 and approximately $8 for each month from July 1, 2018 for sales and marketing services performed for the Company, on a part time basis, by two Freehold sales representatives through June 2018 and one Freehold sales representative from July 2018 to September 2018 (the “FreeHold Services”).2018. As of September 30, 2018 and December 31, 2017,2018, the Company had $8 and $50$0 recorded as accounts payable to FreeHold, respectively.FreeHold. For the three and nine months ended September 30, 2018, the Company recorded $25 and $175,$100, respectively, as general and administrative expense related to this arrangement. For the three and nine months ended September 30, 2017, the Company recorded $0 as general and administrative expense related to this arrangement.

 

Note 78Stockholder’sShareholders’ Equity

 

Initial Public OfferingIssuance of Common Stock

 

On February 16,March 5, 2019, the Company issued 10,313 shares of its common stock related to the vested portion of the restricted stock unit award granted on October 1, 2018 to the Chief Executive Officer (the “CEO”) for 165,000 shares of common stock.

On July 1, 2019 the Company closed its IPOan underwritten public offering in which it sold 3,500,0006,666,667 shares of the Company’s common stock at a public offering price of $5.00$3.00 per share. In connection with the closing of the IPO, (1)offering, the Company received net proceeds of approximately $15,000$18,241 after deducting underwriting discounts and commissions of $1,400$1,500 and other offering expenses of approximately $1,100, (2) the amendment to the registration rights agreement described below became effective, (3) the amendment to the Certificate of Designation described above in Note 5 became effective, (4) all outstanding shares of Series A Convertible Preferred Stock converted, on a one-to-one basis, into shares of the Company’s common stock, (5) the Company issued the Royalty Payment Rights Certificates as described in Note 5, and (6) the Company issued warrants to certain of the former Series A Convertible Preferred Stock and common stock holders, pursuant to the amendment to the Registration Rights Agreement, the amendment to the Certificate of Designation, and the execution of a lock up agreement, to purchase an aggregate of 1,095,682 shares of the Company’s common stock (the “Ten Percent Warrants”). The Ten Percent Warrants are exercisable any time on or after the 180-day anniversary of the completion of the IPO, have a five-year term, and provide for cashless exercise.$259. In addition, the Company granted the representative of the several underwriters in the IPOoffering (the “Representative”) a 30-day option (the “Over-Allotment Option”) to purchase up to an aggregate 525,0001,000,000 additional shares of the Company’s common stock at an exercise price of $5.00$3.00 per share.


Motus GI Holdings, Inc. and Subsidiaries

The Ten Percent Warrants were valued usingNotes to the Black-Scholes option pricing model under the following assumptions, (i) expected life of 5 years, (ii) volatility of 67.08%, (iii) risk-free rate of 2.63%,Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and (iv) dividend rate of zero. For the three and nine months ended September 30, 2018, the Company recorded $0 and $3,156 for the fair value of the Ten Percent Warrants as warrant expense in the accompanying condensed consolidated statements of comprehensive loss.per share amounts)

 

On March 12, 2018,July 10, 2019, the Company issuedclosed the sale of an additional 56,000648,333 shares of its common stock at a price of $5.00$3.00 per share, pursuant to the Representative’s partial exercise of the Over-Allotment Option. In connection with the closing of the partial exercise of the Over-Allotment Option, the Company received additional net proceeds of $258$1,789 after deducting underwriting discounts and commissions of $22.$156.

 

On August 20, 2019, the Company issued 30,140 shares of its common stock to the CEO and executives related to the vested portion of the restricted stock unit awards granted on October 1, 2018 to the CEO for 165,000 shares of common stock and on February 13, 2019 to executives for 76,112 shares of common stock.

Issuance of Common Stock and Warrants to Purchase Common Stock

On March 27, 2018, the Company’s Board of Directors approved the issuance of 15,000 shares of the Company’s common stock to a third party for services to be provided. The stock vests immediately and is subject to a lock-up through February 14, 2019. The Company recorded the fair market value of the stock on the date of issuance as stock-based compensation in the amount of $69.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

 

On June 6, 2018, the Company entered into a consultant agreement with a service provider which shall continue until the agreement is terminated by the Company or service provider by providing at least five business days’ prior written notice. Pursuant to the agreement, the Company (a) issued a warrant on June 6, 2018 to purchase 10,000 shares of the Company’s common stock, with an exercise price of $5.25 per share, at which time a measurement date was reached (b) upon the four (4) month anniversary of the execution of the agreement, provided the service provider is still engaged at that time, will issueissued a warrant on October 6, 2018 to purchase 10,000 shares of the Company’s common stock, with an exercise price of $6.25 per share at which time a measurement date was reached, and (c) upon the eight (8) month anniversary of the execution of the agreement, provided the service provider is still engaged at that time, will issueissued a warrant on February 6, 2019 to purchase 10,000 shares of the Company’s common stock, with an exercise price of $7.25 per share (collectively, such warrants referred to as the “Consultant Warrants”). The Consultant Warrants will each have a five-year term, vest immediately, and will provide for cashless exercise. Warrants totaling 30,000 in relation to this agreement were valued using the Black-Scholes option pricing model under the following assumptions, (i) expected life of 5 years, (ii) volatility of 67.25%, 67.28%, and 69.57%,69.23% (iii) risk-free rate of 2.51%, 2.81%, and 2.94%3.07%, and (iv) dividend rate of zero. The fair value of the 30,000 warrants was initially estimated to be $95 at the inception of the agreement. On January 1, 2019, upon adoption of ASU 2018-07, the fair value was re-measured which approximated the fair value as of December 31, 2018 of $76 which is expensed using the straight-line method over eight months. The Company recorded $0 and $10 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss in relation to the 30,000 warrants for the three and nine months ended September 30, 2019, respectively. The Company recorded $38 and $45 as general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss in relation to the 30,000 warrantsconsulting agreement for the three and nine months ended September 30, 2018, respectively.

 

On July 2, 2018, the Company entered into a consultant agreement with a service provider which shall continuecontinued until February 28, 2019, unless and until sooner terminated by the Company or service provider by providing, at any time after October 2, 2018, at least five business days’ prior written notice.2019. Pursuant to the agreement, the Company (i) issued a fully-vested and nonforfeitable warrant on July 2, 2018 (at which point a measurement date was reached) to purchase 25,000 shares of the Company’s common stock, with an exercise price of $7.39 per share, and expiresexpired 12 months from the date of agreement, (ii) issued a fully-vested and nonforfeitable warrant on July 2, 2018 (at which point a measurement date was reached) to purchase 25,000 shares of the Company’s common stock, with an exercise price of $7.39 per share, and expires 18 months from the date of the agreement, (iii) upon the three (3) month anniversary of the date of the agreement, provided the service provider is still engaged at that time, will issueissued a fully-vested and nonforfeitable warrant on October 2, 2018 (at which point a measurement date was reached) to purchase 25,000 shares of the Company’s common stock with an exercise price of $8.75 per share, and expires 18 months from the date of the agreement and (iv) upon the six (6) month anniversary of the date of the agreement, provided the service provider is still engaged at that time, will issueissued a fully-vested and nonforfeitable warrant on January 2, 2019 to purchase 25,000 shares of common stock of the Company with an exercise price of $10.00 per share, and expires 24 months from the date of the agreement. The warrants issued under this agreement are callable by the Company and it will have the right to require the consultant to exercise all or any warrants still unexercised for a cash exercise or the Company may re-purchase the warrant at a price of $0.01 per warrant share if the Company’s stock trades above a closing floor price ranging from $9.00 to $13.00 per share for ten (10) consecutive trading days. In accordance with FASB ASC 480, the call feature is a conditional obligation upon an event not certain to occur that becomes mandatorily redeemable if that event occurs, the condition is resolved, or that event becomes certain to occur. Because the conditional event is within control of the Company, the call feature is not recognized for accounting purposes until the Company exercises its rights under agreement. Warrants totaling 100,000 in relation to this agreement were valued using the Black-Scholes option pricing model under the following assumptions, (i) expected life of 1-2 years, (ii) volatility of 61.86%62.04% - 65.84%, (iii) risk-free rate of 2.342.34% - 2.81%2.66%, and (iv) dividend rate of zero. The aggregate fair value of the 100,000 warrants was initially estimated to be $146 and was re-measured on January 1, 2019, upon the adoption of ASU 2018-07, which will beapproximated the fair value as of December 31, 2018 of $126 which was expensed using the straight-line method over eight months. The Company recorded $0 and $31 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss for the three and nine months ended September 30, 2019, respectively. The Company recorded $55 as general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss for both the three and nine months ended September 30, 2018. As of September 30, 2019 and December 31, 2018, the Company has recorded a prepaid expense in the amount of $52,$0 and $27, respectively, related to the fully vested nonforfeitable shares of common stock and warrants issued for which services have not been rendered.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

 

On July 3, 2018, the Company entered into an amendment to a consulting agreement dated May 27, 2017 as a continuation of investor relation and consulting services to extend the termination of the agreement to July 2019 and issued 30,000 shares of common stock which vestsvested immediately and a warrant to purchase 90,000 shares of common stock which vestsvested immediately. The warrants are fully vested, are exercisable at $8.50 per share and expire five years from the date of issuance. The 90,000 warrants were valued using the Black-Scholes option pricing model under the following assumptions, (i) expected life of 5 years, (ii) volatility of 68.31%, (iii) risk-free rate of 2.72%, and (iv) dividend rate of zero. The fair value of the 90,000 warrants and 30,000 shares of common stock was estimated to be $594 which will be expensed using the straight-line method over thirteen months, the expected term of the agreement. The Company recorded $41 and $317 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss for the three and nine months ended September 30, 2019, respectively. The Company recorded $136 as general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss for both the three and nine months ended September 30, 2018. As of September 30, 2019 and December 31, 2018, the Company has recorded a prepaid expense in the amount of $454,$0 and $317, respectively, related to the fully vested nonforfeitable shares of common stock and warrants issued for which services have not been rendered.

 

On January 1, 2019, the Company entered into an amended and restated consultant agreement to restate and replace the existing consultant agreement dated October 1, 2018 with a service provider which shall continue until September 30, 2019, unless and until sooner terminated by the Company or service provider by providing at least thirty days prior written notice. Pursuant to the agreement, the Company issued a fully-vested and nonforfeitable warrant on February 13, 2019 to purchase 50,000 shares of the Company’s common stock, with an exercise price of $5.00 per share, and expires March 20, 2022. The warrants were valued using the Black-Scholes option pricing model under the following assumptions, (i) expected life of 3 years, (ii) volatility of 67.43%, (iii) risk-free rate of 2.52%, and (iv) dividend rate of zero. The aggregate fair value of the 50,000 warrants was estimated to be $90 which will be expensed using the straight-line method over nine months. The Company recorded $30 and $90 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss for the three and nine months ended September 30, 2019, respectively.

On February 13, 2019, the Company issued to an existing service provider for past services rendered a fully-vested and nonforfeitable warrant to purchase 30,000 shares of the Company’s common stock, with an exercise price of $5.00 per share, and expires March 20, 2022. The warrants were valued using the Black-Scholes option pricing model under the following assumptions, (i) expected life of 3 years, (ii) volatility of 67.43%, (iii) risk-free rate of 2.52%, and (iv) dividend rate of zero. The aggregate fair value of the 30,000 warrants was estimated to be $55. The Company recorded $0 and $55 as general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2019.

On August 1, 2019, the Company entered into a consulting agreement which shall continue until the agreement is terminated by the Company or service provider by providing at least ten business days’ prior written notice. On September 16, 2019, the Company issued a notice of termination to the service provider to terminate the consulting agreement on November 30, 2019. Pursuant to the agreement, the Company issued two warrants on August 8, 2019 to purchase an aggregate of 20,000 shares the Company’s common stock, with an exercise price of $2.66 per share (the “August 2019 Consultant Warrants”), which vest for four equal tranches beginning November 1, 2019 through August 1, 2020. On November 13, 2019, the Company’s board of directors accelerated the vesting of the August 2019 Consultant Warrants which will vest in their entirety on November 30, 2019. The August 2019 Consultant Warrants have a three-year term and provide for a cashless exercise. The August 2019 Consultant Warrants were valued using the Black-Scholes option pricing model under the following assumptions, (i) expected life of 3 years, (ii) volatility of 69.36%, (iii) risk-free rate of 1.71%, and (iv) dividend rate of zero. The aggregate fair value of the August 2019 Consultant Warrants was estimated to be $18 which will be expensed using the straight-line method from August 8, 2019 through November 30, 2019. The Company recorded $8 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss for both the three and nine months ended September 30, 2019.


20

Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

Consultant Award

 

On July 3, 2018, the Company engaged an executive search firm (the “Firm”) to conduct a confidential search for a Chief Executive Officer (the “CEO”) for the Company. The terms of the engagement were that upon a successful search, the Company would compensate the Firm one-third of the total first-year actual cash compensation for the position. The Company agreed to (a) make payments based on the CEO’s base salary of $475, and (b) make a true-up payment (the “True-up Payment”) at the end of the CEO’s first year of employment basebased on the actual cash compensation earned within the CEO’s first year of employment, exclusive of any Employment Buy-Out Payments.

 

The recruiter was successful in recruiting a new CEO for the Company. An employment agreement was finalized and entered into during the third quarter of 2018 and effective October 1, 2018. The Company deemed the Firm’s services were rendered in the third quarter of 2018 as an employment agreement was finalized in September 2018. The CEO’s annual base salary is $475 and is entitled to bonus and Employment Buy-Out Payments.

 

Firm Compensation

 

The Firm’s total compensationCompany entered into an agreement on August 30, 2019 with the Firm which superseded the True-up Payment. The Company agreed the final amount due to the Firm is to be paid 75% in cash and 25% in equity in the form of a warrant valued per the last round valuation. The cash component for the initial base salary measurement for $119 is payable in three (3) monthly installments with the first installment dated at the start date of the engagement. Therefore, the first installment was dated July 3, 2018; since, the Company deemed the services began in July 2018.

The Firm’s total compensation is the aggregate of one-third of the base salary of $475 and one-third of any additional cash compensation earned within the CEO’s first year of employment. As of September 30, 2018, the Company owes the following payments: (i) a warrant (the “Base Warrant”) and cash payment based on one-third of the base salary of $475, (ii) a warrant (the “Contingent Warrant”) based on any additional cash compensation earned by the CEO during his first year of employment, and (iii)as follows: (a) a cash payment basedof $57 which was paid on any additional cash compensation earned byOctober 4, 2019, and (b) a fully-vested and nonforfeitable warrant to purchase 6,333 shares of the CEO during his first year of employment. For items (ii) and (iii), a True-up Payment will be determined after the first year of employment ends and the additional cash compensation is known.

Warrant Accounting

Each warrant will be issuedCompany’s common stock, with an exercise price of $5$3.00 per share subject to adjustment with(the “November 2019 Consultant Warrant”). The November 2019 Consultant Warrant, which has a three-year term, to purchase shares of the Company’s common stock. was not issued until November 13, 2019.

Consultant Liability

As of September 30, 2018, the warrants have not been issued but will be fully vested upon issuance.

Consultant Expense

The Company valued the entire agreement2019 and recorded $239 as general and administrative expense for the three and nine months ended September 30, 2018 as follows: (i) $158 earned for one-third of $475 payable 75% in cash and 25% by issuing a variable number of warrants, and (ii) $81 for the estimated cash portion of the True-up Payment that will also be paid 75% in cash and 25% by issuing a variable number of warrants. As of September 30,December 31, 2018, the Company has recorded in the aggregate $190accrued $62 and $93, respectively, in accounts payable and accrued expenses in relation to this agreement.


Motus GI Holdings, Inc. and Subsidiaries

Notes tofor the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)True-up Payment.

 

Employment Buy-Out PaymentsWarrants

The Firm agreed not to include any Employment Buy-Out Payments stipulated in the agreement as a calculation in the Firm’s fee as these Employment Buy Out Payments were deemed to be earned at the CEO’s previous place of employment. The Employment Buy-Out Payments represent any cash and equity bonuses earned that the CEO forfeited upon departing his previous place of employment, thus the Employment Buy-Out Payments will not be considered in the True-up Payment.

 

A summary of the Company’s warrants to purchase common stock activity is as follows:

 

   Shares Underlying Warrants  Weighted Average Exercise Price  Weighted average Remaining Contractual Life (years)  Aggregate Intrinsic Value 
Outstanding at December 31, 2017   1,340,869  $5.07   3.73  $ 
Granted   1,245,682   5.35       110 
Outstanding at September 30, 2018   2,586,551  $5.20   3.76  $241 
  Shares Underlying Warrants  Weighted Average Exercise Price  Weighted Average Remaining Contractual Life (years)  Aggregate Intrinsic Value 
Outstanding and exercisable at December 31, 2018  2,629,468  $5.24   3.58  $      - 
Granted  135,000   5.75         
Expired  (25,000)  7.39         
Outstanding at September 30, 2019  2,739,468  $5.25   2.83  $- 

 

ExerciseAs of Options

On February 21, 2018, a consultant exercised 896 options on a cashless basis which resulted in the issuance of 394 shares of the Company’s common stock.

On July 5, 2018, the Company issued 773 shares of its common stock upon the exercise of 773 employee options at an exercise price of $4.50 per share. In connection with the exercise, the Company received $3 in proceeds.

On July 31, 2018, the Company issued 1,792 shares of its common stock upon the exercise of 1,792 employee options at an exercise price of $2.52 per share. In connection with the exercise, the Company received $5 in proceeds.

On August 23, 2018, the Company issued 3,943 shares of its common stock upon the exercise of 3,943 employee options at an exercise price of $2.38 per share. In connection with the exercise, the Company received $9 in proceeds.

On August 23, 2018, the Company issued 2,389 shares of its common stock upon the exercise of 2,389 employee options at an exercise price of $2.52 per share. In connection with the exercise, the Company received $6 in proceeds.

On September 14, 2018, the Company issued 5,000 shares of its common stock upon the exercise of 5,000 employee options at an exercise price of $4.50 per share. In connection with the exercise, the Company received $23 in proceeds.

On September 14, 2018, the Company issued 499 shares of its common stock upon the exercise of 499 employee options at an exercise price of $5.00 per share. In connection with the exercise, the Company received $2 in proceeds.

30, 2019, 2,719,468 warrants were exercisable.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)


(In thousands, except share and per share amounts)

 

Stock Options

Exercise of Options

On January 31, 2019, the Company issued 416 shares of its common stock upon the exercise of 416 employee options at an exercise price of $3.78 per share. In connection with the exercise, the Company received $2 in proceeds.

A summary of the Company’s stock option activity is as follows:

  Shares Underlying Options  Weighted Average Exercise Price  Weighted Average Remaining Contractual Life (years)  Aggregate Intrinsic Value 
Outstanding at December 31, 2018  2,520,101  $4.32   8.72  $         - 
Granted  1,242,144   4.02         
Exercised  (416)  3.78       * 
Forfeited/cancelled  (189,632)  4.38         
Outstanding at September 30, 2019  3,572,197  $4.22   8.50  $- 

*represents amount less than $1,000

 

The following table summarizes stock option activityoptions granted during the nine months ended September 30, 2018:2019 and 2018 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

 

   Shares Underlying Options  Weighted Average Exercise Price  Weighted average Remaining Contractual Life (years)  Aggregate Intrinsic Value 
Outstanding at December 31, 2017   1,803,094  $4.41   9.19  $334 
Granted   252,000   4.99         
Exercised   (15,292)  3.31       33 
Forfeited/canceled   (75,348)  4.60         
Outstanding at September 30, 2018   1,964,454  $4.48   8.63  $1,279 
  For the nine months ended
September 30,
 
  2019  2018 
Expected term, in years  5.8   5.7 
Expected volatility  78.02%  68.12%
Risk-free interest rate  2.34   2.76%
Dividend yield  -   - 
Grant date fair value $2.64  $3.07 

 

At September 30, 2018,2019, unamortized stockshare based compensation for stock options was $2,070,$4,163, with a weighted-average recognition period of 1.031.17 years.

 

At September 30, 2018,2019, outstanding options to purchase 1,013,4621,742,201 shares of common stock were exercisable with a weighted-average exercise price per share of $4.40.$4.37.

 

For the three and nine months ended September 30, 2019, the Company recorded $578 and $1,811, respectively, for share based compensation expense related to stock options.

For the three and nine months ended September 30, 2018, the Company recorded $415 and $1,155, respectively, for share based compensation expense related to stock options.

 

ForRestricted Stock Units

On February 13, 2019, the Company granted 76,112 restricted stock unit awards to executives which vest over a four-year period on a quarterly basis. The aggregate fair value of the restricted stock unit awards granted was estimated to be $329 which is expensed using the straight-line method over a four-year period.

The Company recorded $73 and $208 as general and administrative expense in the accompanying condensed consolidated statement of comprehensive loss for the three and nine months ended September 30, 2017,2019, respectively, in relation to the Company recorded $410aggregate 241,112 restricted stock units issued to date to the CEO and $1,436 for stock options.executives.


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)
(In thousands, except share and per share amounts)

 

A summary of the Company’s restricted stock unit awards activity is as follows:

  Number of Shares  Weighted Average Grant Date Fair Value 
Nonvested at December 31, 2018  165,000  $810 
Granted  76,112   329 
Vested  (40,453)  (193)
Nonvested at September 30, 2019  200,659  $946 

At September 30, 2019, unamortized stock compensation for restricted stock units was $882, with a weighted-average recognition period of 1.68 years.

Stock Based Compensation

 

The following table sets forth total non-cash stock-based compensation for the issuance of common stock, options to purchase common stock, and warrants to purchase common stock, and restricted stock unit award by operating statement classification for the three and nine months ended September 30, 20182019 and 2017:2018:

 

 Three Months ended September 30, Nine Months ended September 30,  Three Months ended September 30,  Nine Months ended September 30, 
 2018 2017 2018 2017  2019  2018  2019  2018 
Research and development $32  $110  $135  $158  $182  $32  $467  $135 
Sales and marketing  58   86   97   123   93   58   221   97 
General and administrative  572   1,100   1,503   1,613   455   572   1,842   1,503 

Total(1), (2)

 $662  $1,296  $1,735  $1,894 
Total(1)(2) $730  $662  $2,530  $1,735 

(1)As of September 30, 20182019 and 2017,December 31, 2018, the Company recorded a prepaid expense in the amount of $506$0 and $0$344, respectively, for the value of vested warrants for future services to be rendered.
(2)As of September 30, 20182019 and 2017,December 31, 2018, the Company recorded a warrant liability in the amount of $48$5 and $0$22, respectively, for the value of warrants to be issued for services provided.

For options granted during the nine months ending September 30, 2018 were valued using the Black-Scholes option pricing model using the following weighted average assumptions: (i) expected life of 5.7 years, (ii) volatility of 68.12%, (iii) risk free interest rate of 2.76% and (iv) dividend yield of zero.

2016 Equity Incentive Plan

The Company has 2,641,250 shares of common stock reserved for issuance and as of September 30, 2018 there were 653,272 shares available for grant under the Company’s equity plan. The Company has one equity incentive plan that was adjusted in 2016. The number of shares of common stock available for issuance under the Company’s equity plan shall increase annually by six percent (6%) of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year; provided, however, that the board of directors may act prior to the first day of any calendar year to provide that there shall be no increase such calendar year, or that the increase shall be a lesser number of shares of our common stock than would otherwise occur.

 

Note 89 – Subsequent Events

 

The Company has analyzed its operations subsequent to September 30, 20182019 and noted the following subsequent events:

 


Motus GI Holdings, Inc. and Subsidiaries

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(In thousands, except share and per share amounts)

Options and Warrants

On October 2, 2018, the Company issued a warrant to purchase 25,000 shares of the Company’s common stock with an exercise price of $8.75 per share and an exercise period of 18 months in connection with an agreement entered into on July 2, 2018 (see Note 7).

On October 6, 2018, the Company issued a warrant to purchase 10,000 shares of the Company’s common stock with an exercise price of $6.25 per share and an exercise period of five years in connection with an agreement entered into on June 6, 2018 (see Note 7).

On October 31, 2018, the Company gave thirty-day notice to FreeHold, a related party, for termination of its services agreement effective November 30, 2018.

On November 8, 2018, the Company’s Compensation Committee approved the issuance of 560,000 options to employees which vest over a three-year period on a quarterly basis to purchase shares of the Company’s common stock at $3.78, the closing share price of the Company’s common stock on the Nasdaq Capital Market on November 8, 2018.

On November 8, 2018,13, 2019 the Company’s Board of Directors approved the issuance of a warrantthe November 2019 Consultant Warrant to a consultantthe Firm, which vests immediately to purchase 7,9176,333 shares of the Company’s common stock at an exercise price of $5$3.00 per share in accordance with the consulting agreement entered into on July 2, 2018 (see Note 7 -Consultant Award).

which have a three-year term.


Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Item 2. MANAGEMENT’S DISCUSSION AND ANLAYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under “Risk Factors.”

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

 

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

 

our limited operating history;

our history of substantial operating losses in each year since inception and expectation that we will continue to incur substantial operating losses for the foreseeable future;

our current and future capital requirements to support our development and commercialization efforts for the Pure-Vu systemSystem and our ability to satisfy our capital needs;

our dependence on the Pure-Vu system,System, our sole product candidate, which is still in development;

our ability to obtain approval from regulatory agents in different jurisdictions for the Pure-Vu system;System;

our Pure-Vu systemSystem and the procedure to cleanse the colon in preparation for colonoscopy are not currently reimbursable through private or governmental third-party payors;

our lack of a developed sales and marketing organization and our ability to commercialize the Pure-Vu system;System;

our dependence on third-parties to manufacture the Pure-Vu system;System;

our ability to maintain or protect the validity of our patents and other intellectual property;

our ability to retain key executives and medical and science personnel;

our ability to internally develop new inventions and intellectual property;

interpretations of current laws and the passages of future laws;

acceptance of our business model by investors;

the accuracy of our estimates regarding expenses and capital requirements; and

our ability to adequately support growth.


The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipateanticipated in our forward-looking statements. Please see “Part II—Item 1A—Risk Factors” for additional risks which could adversely impact our business and financial performance.

 

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.

 


Overview

 

We have developed the Pure-Vu System, a single-use medical device system (the “Pure-Vu system”), cleared bythat has received 510(k) clearance from the United StatesU.S. Food and Drug Administration (the “FDA”(“FDA”). In June 2019, the 510(k) premarket notification for the second-generation of the Pure-Vu System was reviewed and whichcleared by the FDA. The first-generation of our Pure-Vu System has received CE Mark approval in the European Economic Area, thatand we intend to seek CE Mark approval for the second generation of our Pure-Vu System. The Pure-Vu System is intended to attach to standard colonoscopesindicated to help facilitate intraproceduralthe cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter. The Pure-Vu system has been designed to integrate with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care for a hospital in a market segment where most of the reimbursement is under a bundle payment based on a Diagnostic Related Group (a “DRG”)., comprising of approximately 1.5 million annual inpatient colonoscopy procedures in the U.S. and approximately 3.8 million annual inpatient colonoscopy procedures worldwide. The Pure-Vu systemSystem does not currently have a unique reimbursement code with any private or governmental third-party payors in any country. To date,We began commercialization in October 2019, with the first commercial placements of our second generation Pure-Vu System as part of the limitedour initial U.S. market development launch we have focused on collecting additional clinical and health economic data, as exemplified by the recently initiated Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement Study (the “REDUCE Study”), along with garnering valuable experience in key hospitals on the use of the Pure-Vu system to support a full launch in the United States inpatient market in 2019.targeting early adopter hospitals. We do not expect to generate significant revenue from product sales unless and until we expand our commercialization efforts. efforts for the Pure-Vu System, which is subject to significant uncertainty.

 

Public Offering

On July 1, 2019 we closed an underwritten public offering in which we sold 6,666,667 shares of our common stock at a public offering price of $3.00 per share. In connection with the closing of the offering, we received net proceeds of approximately $18.2 million after deducting underwriting discounts and commissions of approximately $1.5 million and other offering expenses of approximately $0.3 million. In addition, we granted the representative of the several underwriters in the offering (the “Representative”) a 30-day option (the “Over-Allotment Option”) to purchase up to an aggregate 1,000,000 additional shares of our common stock at an exercise price of $3.00 per share. In connection with the closing of the partial exercise of the Over-Allotment Option, on July 10, 2019 we sold 648,333 shares of our common stock at an exercise price of $3.00 per share and received additional net proceeds of approximately $1.8 million after deducting underwriting discounts and commissions of approximately $0.2 million.

Financial Operations Overview

 

We are a development stage company and have not generated any significant revenues from the sale of products. We have never been profitable and our accumulated deficit as of September 30, 20182019 was approximately $55.8$78.5 million. Our net losses for the three months ended September 30, 2018 and 2017 were approximately $5.2 million and $3.2 million, respectively, andloss for the nine months ended September 30, 2019 and 2018 was approximately $17.1 million and 2017 our net losses were approximately $16.7 million and $9.4 million, respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future. We expect our expenses to increase significantly in connection with our ongoing activities to commercialize and market the Pure-Vu system.System. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.


We expect to continue to incur significant expenses and increasing operating losses for at least the next several years.

We expect our expenses will increase substantially in connection with our ongoing activities, as we:

 

begin commercialization in October 2019, with the first commercial placements of our Pure-Vu System as part of our initial U.S. market launch targeting early adopter hospitals;

conduct a limited market development launch through 2018 and into the first part of 2019 to refine how the Pure-Vu system integrates into the workflow of the in-patient settings and hone the value proposition and health economic benefits to hospitals;
workscale manufacturing with third parties to scale up the manufacture ofour contracted partners for both the workstation and disposable portions of the disposable portion of Pure-Vu system;System;

develop a second generation systemfuture generations of the Pure-Vu System to improve user interface, optimize ease of usehandling and reduce the cost structure;

raise sufficient funds in the capital market to effectuate our business plan, including commercialization activities related to our Pure-Vu systemSystem and our research and development activities, including clinical and regulatory development and the continued development and enhancement of our Pure-Vu system;System; and

 


operate as a public company.

 

Critical Accounting Policies and Estimates

 

Our accounting policies are essential to understanding and interpreting the financial results reported on the condensed consolidated financial statements. The significant accounting policies used in the preparation of our condensed consolidated financial statements are summarized in Note 23 to the consolidated financial statements and notes thereto found in our Annual Report on Form 10-K for the year ended December 31, 2017.2018. Certain of those policies are considered to be particularly important to the presentation of our financial results because they require us to make difficult, complex or subjective judgments, often as a result of matters that are inherently uncertain.

 

During the nine months ended September 30, 2018,2019, there were no material changes to matters discussed under the heading “Critical Accounting PolicesPolicies and Estimates” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 20172018 except for the following:

 

Revenue RecognitionLeases

 

In May 2014,February 2016, the Financial Accounting Standards Board (FASB)FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09) “Revenue from Contracts2016-02, Leases (Topic 842) (“ASU 2016-02”), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. On January 1, 2019, we adopted the new lease standard using the optional transition method under which comparative financial information will not be restated and continue to apply the provisions of the previous lease standard in our annual disclosures for the comparative periods. In addition, the new lease standard provides a number of optional practical expedients in transition. We elected the package of practical expedients. As such, we did not have to reassess whether expired or existing contracts are or contain a lease; did not have to reassess the lease classifications or reassess the initial direct costs associated with Customers.” ASU 2014-09 supersedesexpired or existing leases.

The new lease standard also provides practical expedients for an entity’s ongoing accounting. We elected the revenueshort-term lease recognition requirements in “Revenue Recognition (Topic 605)”,exemption under which we will not recognize right-of-use (“ROU”) assets or lease liabilities, and requires entitiesthis includes not recognizing ROU assets or lease liabilities for existing short-term leases. We elected the practical expedient to recognize revenue when it transfers promised goodsnot separate lease and non-lease components for certain classes of assets (facilities).


On January 1, 2019, we recognized ROU assets of approximately $1.1 million and lease liabilities of approximately $1.1 million and no adjustment was made to our accumulated deficit. The adoption of the new lease standard did not impact our condensed consolidated statement of comprehensive loss or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services.our condensed consolidated statement of cash flows.

 

We adopted ASU 2014-09 effective January 1, 2018determine if an arrangement is a lease at inception. For our operating leases, the ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Since all of the lease agreements do not provide an implicit rate, we estimated an incremental borrowing rate in determining the present value of the lease payments. Operating lease expense is recognized on a full retrospective basis. Adoption of this standard did not resultstraight-line basis over the lease term, subject to any changes in significant changes to accounting policies, business processes, systemsthe lease or controls, or have a material impact onexpectations regarding the financial position, results of operationsterms. Variable lease costs such as operating costs and cash flows or related disclosures. As such, prior period financial statements were not recast.property taxes are expensed as incurred.

 

Short-term Investment SecuritiesStock Based Compensation

Adoption of Accounting Standards Update 2018-07

 

We investhave adopted Accounting Standards Update 2018-07 (ASU 2018-07), “Improvement to Nonemployee Share-based Payment Accounting”, which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new guidance will be applied prospectively to all excess cash primarily in debt securities.

Short-term investments that we havenew awards granted after the positive intent and abilitydate of adoption. In addition, the new guidance will be applied to hold to maturity are classified as held-to-maturity and are carried at amortized cost. Purchase premiums and discounts are recognized in finance income, net overall existing equity-classified awards for which a measurement date has not been established under ASC 505-50 by the term of the investment. Short-term investments not classified as held-to-maturity investments are classified as available-for-sale investments and recordedadoption date by remeasuring at fair value with unrealized gainsas of the adoption date, and losses reported in other comprehensive income. Gainsrecording a cumulative effect adjustment to opening accumulated deficit on January 1, 2019.

For our equity-classified awards for which a measurement date has not been established under ASC 505-50, the fair value on January 1, 2019, the adoption date, approximated the value assigned on December 31, 2018, therefore no cumulative adjustment to opening accumulated deficit is required.

Under the revised guidance, the accounting for awards issued to nonemployees will be similar to the model for employee awards, except that ASU 2018-07:

allows us to elect on an award-by-award basis to use the contractual term as the expected term assumption in the option pricing model, and

the cost of the grant is recognized in the same period(s) and in the same manner as if the grantor had paid cash.

Employee and losses on the sale of available-for-sale investments are recorded on the trade date.Non-Employee Stock Based Compensation

 

We evaluate whether available-for-saleapply ASC 718-10, “Share-Based Payment,” which requires the measurement and held-to-maturity investments are other-than-temporarily impaired (OTTI)recognition of compensation expenses for all share-based payment awards made to employees and directors including employee stock options under the Company’s stock plans and equity awards issued to non-employees based on estimated fair values.

ASC 718-10 requires companies to estimate the fair value of equity-based option awards on the date of grant using an option-pricing model. The fair value of the award is recognized as an expense on a quarterly basis. Debt securities with unrealized lossesstraight-line basis over the requisite service periods in our condensed consolidated statement of comprehensive loss. We recognize share-based award forfeitures as they occur.

We estimate the fair value of granted option equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are considered OTTI if we intend to sell the security or if it is more likely than not that we will be required to sell such security prior to any anticipated recovery. If we determine that a security is OTTI under these circumstances, the impairment recognized in earnings is measured as the entire difference between the amortized costshare price, expected volatility and the then-currentexpected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. We have historically not paid dividends and have no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value. Duringvalue of the threeoptions granted and nine months endedthe results of our operations.


Restricted Stock Units

We issue restricted stock units under our 2016 Equity Incentive Plan. The fair value of the restricted stock units is based on the closing stock price on the date of grant and is expensed as operating expense over the period during which the units vest. Each restricted stock unit entitles the grantee to one share of common stock to be received upon vesting up to four years after the grant date. Recipients of restricted stock units have no voting rights until the vesting of the award.

Results of Operations

Comparison of Three Months Ended September 30, 2019 and 2018 no investment OTTI losses were realized.

 

Our investment policy is focused on the preservation of capital, liquidity and return. From time to time, we may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price.Revenue

 

Revenue

To date,Through September 30, 2019, as part of our limited launch, we have generated limitedminimal revenue from the sales of products. We do not expect to generate significant revenue from product sales unless and until we expand our commercialization efforts for the Pure-Vu system,System, which we expect will take a number of years and is subject to significant uncertainty.

 


Research

Revenue was approximately $3 thousand and Development

We incurred research and development activity expenses of approximately $1.8 million and $1.0 million, respectively, during$0 for the three months ended September 30, 2019 and 2018, and 2017, and approximately $4.4 million and $2.7 million, respectively, duringrespectively. The increase was attributable to the ninesale of first generation system disposable units. Our sales initiatives are now focused on the second generation system.

Cost of Revenue

Cost of revenue for the three months ended September 30, 20182019 totaled approximately $62 thousand, an increase of approximately $62 thousand over the approximately $0 recorded for the three months ended September 30, 2018. The increase was primarily attributable to the expensing of obsolete raw materials related to the first generation Pure-Vu System in the amount of approximately $57 thousand, the cost of our second generation system disposable evaluation units in the amount of approximately $3 thousand, and 2017. Thesethe cost of selling our first generation system disposable units in the amount of approximately $2 thousand.

Research and Development

Research and development expenses include cash and non-cash expenses relating to the advancement of our development and clinical programs for the Pure-Vu system.System. We have research and development capabilities in electrical and mechanical engineering with laboratories in our facility in Israel for development and prototyping, and electronics design and testing. We also use consultants and third-party design houses to complement our internal capabilities.

 

SalesResearch and Marketing

We incurred sales and marketing activitydevelopment expenses of approximately $1.2 million and $0.6 million, respectively, duringfor the three months ended September 30, 2018 and 2017, and2019 totaled approximately $2.9$2.2 million, and $1.6an increase of approximately $0.4 million respectively, duringover the nineapproximately $1.8 million recorded for the three months ended September 30, 20182018. The increase was primarily attributable to increases of approximately $0.4 million in salaries and 2017. Theseother personnel related cost, approximately $0.1 million in share based compensation, partially offset with approximately $0.1 million decrease in material costs.

Sales and Marketing

Sales and marketing expenses include cash and non-cash expenses relating to the development of our sales and marketing infrastructure for the Pure-Vu system. We have hired limited salesSystem.

Sales and marketing personnel in the U.S. as part of our market development launch to develop our policies and procedures, as well as to spearhead the market development phase of the Company’s market penetration.

General and Administrative Expenses

We incurred general and administrative activity expenses oftotaled approximately $2.1$1.2 million and $2.4 million, respectively, duringfor both the three months ended September 30, 20182019 and 2017,2018. We incurred increases of approximately $0.4 million in salaries and other personnel related cost, partially offset by a decrease of approximately $6.0$0.4 million in marketing and $4.9 million, respectively, during the nine months ended September 30, 2018training product units.


General and 2017. Administrative

General and administrative expenses consist primarily of payroll and professional services. Other general and administrative expensesservices, which include accounting, and legal services, investor relations services, and expenses associated with obtaining and maintaining patents. We anticipate that our general and administrative expenses will increase significantly during the remainder of 2018 and in the future as we increase our headcount and other activities to support our continued development and commercialization activities related toof our Pure-Vu system.System. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations and communication costs associated with being a public company. Additionally, commencing in July 2017, we began to compensate our outside directors.

Stock-Based Compensation

Stock options are granted with an exercise price at no less than fair market value at the date of the grant. The stock options normally expire ten years from the date of grant. Stock option awards vest upon terms determined by our board of directors.

We recognize compensation costs resulting from the issuance of stock-based awards to employees, members of our board of directors and consultants. The fair value of each option grant was estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Due to our limited operating history and limited volume of sales of our common stock, we estimated our volatility in consideration of a number of factors, including the volatility of comparable public companies. The expected term of options granted to employees under our stock plans is based on the simplified method. Under this method, the expected term is equal to the sum of the weighted average vesting term plus the original contractual term, divided by two. We have elected this method as we have concluded that we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time our equity shares have been publicly traded. The vesting period is generally 36 months. The expected term of options granted under the 2016 Equity Incentive Plan (the “2016 Equity Incentive Plan”), all of which qualify as “plain vanilla” per SEC Staff Accounting Bulletin 107, is based on the average of approximately 5.81 years. For non-employee options, the expected term is the contractual term and stock options granted to non-employee consultants are revalued at the end of each reporting period until vested and changes in their fair value are recorded as adjustments to expense over the related vesting period. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the expected term of the option. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. We recognize share-based award forfeitures as they occur rather than estimate by applying a forfeiture rate.


Emerging Growth Company Status

Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Results of Operations

Comparison of Three Months Ended September 30, 2018 and 2017

To date, as part of our limited launch, we have generated limited revenue from the sales of products. We do not expect to generate significant revenue from product sales unless and until we expand our commercialization efforts for the Pure-Vu system, which we expect will take a number of years and is subject to significant uncertainty.

Research and Development

Research and development expenses for the three months ended September 30, 2018 totaled approximately $1.8 million, an increase of $0.8 million over the $1.0 million recorded for the three months ended September 30, 2017. The increase was primarily attributable to increases of $0.3 million in salaries, wages and related, $0.1 million in professional services and subcontractor costs, $0.2 million in material costs, and $0.2 million in travel and other research and development cost.

Sales and Marketing

Sales and marketing expenses for the three months ended September 30, 2018 totaled approximately $1.2 million, an increase of $0.6 million over the $0.6 million recorded for the three months ended September 30, 2017. The increase was primarily attributable to increases of $0.2 million in professional services and subcontractor costs, $0.4 million in marketing and training product units, $0.1 in tradeshow and other promotional items, partially offset by a decrease of $0.1 million in salaries and wages and other costs.

General and Administrative

 

General and administrative expenses for the three months ended September 30, 20182019 totaled approximately $2.1$2.0 million, a decrease of $0.3approximately $0.1 million over the $2.4approximately $2.1 million recorded for the three months ended September 30, 2017.2018. The decrease was primarily attributable to decreases of approximately $0.1 million in share based compensation, approximately $0.2 million in professional and consulting fees, $0.4 million in salaries and wages, partially offset by an increase of $0.3services, approximately $0.1 million in investor and public relation cost.

Other Expensesrelations costs, partially offset with approximately $0.3 million increase in salaries and other personnel related costs.

 

Other expensesIncome and Expenses

Other income, net for the three months ended September 30, 20182019 totaled approximately $0.04$0.2 million compared to $0.8other expense, net of less than $0.1 million of other income recorded for the three months ended September 30, 2017.2018. The $0.8approximately $0.3 million decreasechange in other expenseincome and expenses was primarily attributable to an increase in finance income of approximately $0.1 million, and a gain on the reversalchange in estimated fair value of registration rights expensecontingent royalty obligation for the nine months ended September 30, 2019 in the amount of $0.9approximately $0.1 million compared to a loss on the change in estimated fair value of contingent royalty obligation for the nine months ended September 30, 2018 in the amount of approximately $0.1 million.

 

Comparison of Nine Months Ended September 30, 20182019 and 20172018

 

To date, as partRevenue

Revenue for the nine months ended September 30, 2019 totaled approximately $8 thousand, a decrease of approximately $30 thousand over the approximately $38 thousand recorded for the nine months ended September 30, 2018. The decrease was primarily attributable to the discontinuance of our limited launch,2018 outpatient pilot program under which we have generated limited revenuewere selling first generation system disposable units at a loss. Our market development strategy shifted away from the outpatient sector to the inpatient market and, as a result, this outpatient pilot program was discontinued. Our sales initiatives are now focused on the second generation system.

Cost of products. We do not expect to generate significantRevenue

Cost of revenue from product sales unless and until we expand our commercialization efforts for the nine months ended September 30, 2019 totaled approximately $65 thousand, an increase of approximately $9 thousand over the approximately $56 thousand recorded for the nine months ended September 30, 2018. The increase was primarily attributable to the expensing of obsolete raw materials related to our first generation Pure-Vu System in the amount of approximately $57 thousand, the cost of our second generation system which we expect will take a numberdisposable evaluation units in the amount of years and is subject to significant uncertainty.approximately $3 thousand, partially offset by the decrease in the cost of selling our first generation system disposable units in the amount of approximately $51 thousand.

 


Research and Development

 

Research and development expenses for the nine months ended September 30, 20182019 totaled approximately $4.4$6.7 million, an increase of $1.7approximately $2.3 million over the $2.7approximately $4.4 million recorded for the nine months ended September 30, 2017.2018. The increase was primarily attributable to increases of $0.9approximately $0.5 million of materials purchased and expensed for our first generation Pure-Vu System, approximately $1.2 million in salaries and wages, $0.6 million in professional and subcontractor costs, $0.1other personnel related cost, approximately $0.2 million in travel costs, $0.2approximately $0.3 million in share based compensation, and approximately $0.1 million in other costs, partially offset by a decrease of $0.1 million in clinical related costs.research and development cost.


Sales and Marketing

 

Sales and marketing expenses for the nine months ended September 30, 20182019 totaled approximately $2.9$3.5 million, an increase of $1.3approximately $0.6 million over the $1.6approximately $2.9 million recorded for the nine months ended September 30, 2017.2018. The increase was primarily attributable to increases of $0.6approximately $0.8 million in salaries and other personnel related cost, approximately $0.1 million in marketing and tradeshows, approximately $0.1 million in share based compensation, approximately $0.1 million in travel and other sales and marketing expense, partially offset by a decrease of approximately $0.5 million in marketing and training product units, $0.6 million in professional and subcontractor costs, and $0.1 million travel and other costs.units.

 

General and Administrative

 

General and administrative expenses for the nine months ended September 30, 20182019 totaled approximately $6.0$7.2 million, an increase of $1.1approximately $1.2 million over the $4.9approximately $6.0 million recorded for the nine months ended September 30, 2017.2018. The increase was primarily attributable to increases of $0.4approximately $1.0 million in legalsalaries and professional fees, $0.4other personnel related costs, approximately $0.3 million in investorshare based compensation, and public relation expenses,approximately $0.2 million in insuranceother related expenses,general and $0.2 million in rent, travel and otheradministrative costs, partially offset by a decrease of $0.1approximately $0.3 million in salaries and wages.

Other Expensesprofessional services.

 

Other expensesIncome and Expenses

Other income, net for the nine months ended September 30, 20182019 totaled approximately $3.3$0.3 million compared to $0.2other expenses, net of approximately $3.3 million recorded for the nine months ended September 30, 2017.2018. The $3.1approximately $3.6 million increasechange in other income and expenses was primarily attributable to increases of $3.2 millionthe decrease in warrant expense partially offset byof approximately $3.2 million, a $0.1decrease in loss on change in estimated fair value of contingent royalty obligation of approximately $0.3 million, and an increase in finance income.income of approximately $0.1 million.

 

Liquidity and Capital Resources

 

Since inception, we have experienced negative cash flows from operations. We have financed our operations primarily through sales of equity-related securities. At September 30, 2018,2019, our accumulated deficit since inception was approximately $55.8$78.5 million.

At September 30, 2018, we had total current assets of approximately $12.9 million and total current liabilities of approximately $2.5 million resulting in working capital of $10.4 million. Net cash used in operating activities for the nine months ended September 30, 2018 was approximately $10.5 million, which includes a net loss of approximately $16.7 million, offset by non-cash expenses of approximately $5.8 million principally related to warrant expense of $3.2 million, stock-based compensation expense of $1.8 million, revaluation of contingent royalty obligation of $0.2 million, inventory write-down of $0.5 million, and depreciation and amortization of $0.1 million, and approximately $0.3 million of cash provided by the change in net working capital items principally related to an increase in accounts payable and accrued expenses of $1.1 million, partially offset by an increase in accounts receivable, inventory, prepaid expenses and other current assets, and other long-term assets of $0.8 million and a decrease in other current and long-term liabilities of $0.1 million.

Cash used in investing activities for the nine months ended September 30, 2018 totaled approximately $4.8 million for the purchase of available-for-sale securities of approximately $5.0 million, the purchase of held-to-maturity securities of approximately $4.9 million, and the purchase of fixed assets of approximately $0.2 million, offset by the proceeds from the sale of available-for-sale securities of approximately $2.0 million, the proceeds from the maturity of held-to-maturity securities of $3.1 million, and the proceeds from shareholder loan of approximately $0.1 million.

Cash provided by financing activities for the nine months ended September 30, 2018 totaled approximately $15.3 million. On February 16, 2018, we closed our IPO in which we sold 3,500,000 shares of our common stock at a public offering price of $5.00 per share. In connection with the closing of the IPO, we received net proceeds of approximately $15 million after deducting underwriting discounts and commissions of approximately $1.4 million and other offering expenses of approximately $1.1 million. On March 12, 2018, we received net proceeds of approximately $0.3 million in relation to the sale of an additional 56,000 shares of our common stock at a price of $5.00 per share, pursuant to the Partial IPO Over-Allotment Exercise completed in March 2018.


At September 30, 2018, we had cash and cash equivalents, and short-term investments of approximately $11.6 million. Based on our current business plan, we believe our cash, cash equivalents, and short-term investments balance as of September 30, 2018 will be sufficient to meet our anticipated cash requirements through approximately the second quarter of 2019. However, there is no assurance that the current business plan will be achievable, and such Such conditions raise substantial doubts about our ability to continue as a going concern.

 

At September 30, 2019, we had total current assets of approximately $27.7 million and total current liabilities of approximately $3.5 million resulting in working capital of approximately $24.2 million. Net cash used in operating activities for the nine months ended September 30, 2019 was approximately $14.4 million, which includes a net loss of approximately $17.1 million, offset by non-cash expenses of approximately $2.7 million principally related to share based compensation expense of approximately $2.5 million, and depreciation and amortization of approximately $0.2 million, partially offset by the gain on the change in estimated fair value of contingent royalty obligation of approximately $0.1 million, and offset by changes in net working capital items principally related to the increase in accounts payable and accrued expenses of approximately $0.6 million, and the increase in other current and non-current liabilities of approximately $0.2 million, partially offset with an increase in inventory of approximately $0.7 million.

Net cash used in investing activities for the nine months ended September 30, 2019 totaled approximately $8.0 million principally related to the purchase of available-for-sale securities of approximately $9.6 million, and the purchase of fixed assets of approximately $0.4 million, partially offset with approximately $2.0 million of proceeds from the sale of available for sale securities.

Net cash provided from financing activities for the nine months ended September 30, 2019 totaled approximately $20.0 million principally related to the proceeds received from public offerings and the exercise of over-allotment options of approximately $21.9 million, partially offset by approximately $1.9 million paid for financing fees.

At September 30, 2019, we had cash and cash equivalents, and investments of approximately $26.4 million. We will need to raise significant additional capital to continue to fund operations. We may seek to sell common or preferred equity, convertible debt securities or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholdersshareholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.


The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including some or all of our planned clinical trials.

 

Shelf Registration Statement

On March 26, 2019, we filed a shelf registration statement with the Securities and Exchange Commission, which was declared effective on April 24, 2019, that allows us to offer, issue and sell up to a maximum aggregate offering price of $75.0 million of any combination of our common stock, preferred stock, warrants, debt securities, subscription rights and/or units from time to time, together or separately, in one or more offerings. Each issuance under the shelf registration statement will require the filing of a prospectus supplement identifying the amount and terms of the securities to be issued. As of September 30, 2019 we have sold approximately $22.0 million of securities under our shelf registration statement. Our ability to issue securities is subject to market conditions and other factors including, in the case of our debt securities, our credit ratings.

Off-Balance Sheet Arrangements

 

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.

Item 3.Quantitative and Qualitative Disclosures About Market Risk.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not Applicable.

Item 4.Controls and Procedures.

 

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

 

Evaluation of Our Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report.September 30, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures asAs a result of the period covered by this report for the three and nine months ended September 30, 2018,material weakness in our internal control over financial reporting described below, our Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2018, our disclosure controls and procedures were not effective at the reasonable assurance level due toas of September 30, 2019.

In connection with the review of our third quarter 2018 financial statements and the audit of our annual consolidated financial statements, we identified a material weakness in theour internal control over financial reporting related to the reporting ofaccounting for non-routine complex transactions due to the insufficient complement of personnel with the appropriate level of knowledge to identify and account for these transactions. The material weakness was initially identified when management did not appropriately identify the proper accounting treatment related to a contract that included contingent payments and stock awards owed to a non-employee.

A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected and corrected on a timely basis.

The material weakness did not result in any identified misstatements to the financial statements, and there were no changes to previously released financial results. In light of the material weakness, we performed additional analyses and other post-closing procedures to ensure the Company’s condensedour consolidated financial statements are prepared in accordance with U.S. GAAP. Accordingly, our CEO and CFO have certified that, based on their knowledge, the condensed consolidated financial statements, and other financial information included in this Form 10-Q, fairly present in all material respects theour financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this Form 10-Q.

Management has begun remediation by engaging a third party firm with technical accounting specialists to review the accounting for non-routine complex transactions on a prospective basis. We believe the actions described above will be sufficient to remediate the identified material weakness and strengthen our internal control over financial reporting.


Evaluation of Changes in Internal Control over Financial Reporting

As a newly public company, we continue the process of reviewing and documenting our internal controls over financial reporting, and have implemented new or strengthened existing internal controls over financial reporting during the period to which this report relates, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business. 

Other than as described above, there was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the three months ended September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. From

Remediation Efforts to Address Material Weakness

We began remediation efforts in the fourth quarter of 2018 for our accounting of non-routine complex transactions control by engaging a new third-party firm with technical accounting expertise to review non-routine complex transactions on a prospective basis. We, in consultation with our Audit Committee, continue to evaluate our internal and external technical accounting resources to ensure they are appropriate for us and our needs. We have further evaluated our remediation activities to date, and in addition to utilizing multiple third-party specialists, we have implemented a remediation test plan with our third-party internal control consulting firm. Additionally, there is a renewed emphasis on our process going forward for initial identification of potential contracts and transactions that may be non-routine and complex during a reporting period, and then conducting the necessary procedures with the full internal accounting team and external consultants to review and research the proper guidance and approach toward the accounting, and documenting as such in a white paper or memo as needed.

We believe these measures, and others that may be implemented, will remediate the material weakness in internal control over financial reporting described above.

The material weakness will not be considered formally remediated until the control has operated effectively for a sufficient period of time and management has concluded, through testing, that the control is operating effectively.

Changes in Internal Control over Financial Reporting

Other than the changes intended to time, we make changes toremediate the material weakness noted above, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2019 that are intendedhas materially affected, or is reasonably likely to enhance its effectiveness and which do not have a material effect onmaterially affect, our overall internal control over financial reporting.


PART II — OTHER INFORMATION

Item 1.Legal Proceedings.

Item 1. Legal Proceedings.

 

None.

Item 1A.Risk Factors.

Item 1A. Risk Factors.

 

There have been no material changes in risk factors from what was reported in our 20172018 Annual Report on Form 10-K, other than as described below.10-K.

Risks Related to our Capital Stock

We identified a material weakness in our internal control over financial reporting. If we are not able to remediate the material weakness and otherwise maintain an effective system of internal control over financial reporting, the reliability of our financial reporting, investor confidence in us and the value of our common stock could be adversely affected.

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected and corrected on a timely basis.

In connection with the review of our third quarter 2018 financial statements, we identified a material weakness in our internal control over financial reporting related to the accounting for non-routine complex transactions. Management did not appropriately identify the proper accounting treatment related to contingent payments and stock awards owed to a non-employee. Management has begun remediation by engaging a third party firm with technical accounting specialists to review the accounting for non-routine complex transactions on a prospective basis.

In light of the material weakness, we performed additional analyses and other post-closing procedures to ensure the Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP. Accordingly, our CEO and CFO have certified that, based on their knowledge, the condensed consolidated financial statements, and other financial information included in this Form 10-Q, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this Form 10-Q.

If our steps are insufficient to successfully remediate the material weakness and otherwise establish and maintain an effective system of internal control over financial reporting, the reliability of our financial reporting, investor confidence in us and the value of our common stock could be materially and adversely affected. Effective internal control over financial reporting is necessary for us to provide reliable and timely financial reports and, together with adequate disclosure controls and procedures, are designed to reasonably detect and prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. For as long as we are an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We could be an “emerging growth company” for up to five years from the date of our initial public offering in February 2018, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. 

Moreover, we do not expect that disclosure controls or internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely impact us.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities

 

During the period covered by this Form 10-Q, or such period as described below, we issued the following unregistered securities:

 

In June 2018, we entered into a consultant agreement pursuant to which we (a) issued a warrant, on June 6, 2018, to purchase 10,000 shares of our common stock, with an exercise price of $5.25 per share, (b) issued a warrant, on October 6, 2018, to purchase 10,000 shares of our common stock, with an exercise price of $6.25 per share, and (c) agreed to issue a warrant to purchase 10,000 shares of our common stock, with an exercise price of $7.25 per share, issuable on February 6,August 2019, provided the consultant is still engaged at that time, as payment for services pursuant to the consulting agreement. Each warrant (each a “June 2018 Consultant Warrant”) issued or issuable under the consultant agreement has or will have a five (5) year term and a cashless exercise provision.

In July 2018, we entered into a consulting agreement pursuant to which we (a) issued a warrant on July 2, 2018 to purchase 25,000 shares of our common stock with an exercise price of $7.39 per share, which warrant has an exercise period of 12 months from the date of agreement, (b) issued a warrant on July 2, 2018 to purchase 25,000 shares of our common stock with an exercise price of 7.39 per share, which warrant has an exercise period of 18 months from the date of the agreement, (c) issued a warrant on October 2, 2018 to purchase 25,000 shares of our common stock with an exercise price of 8.75 per share, which warrant has an exercise period of 18 months from the date of the agreement and (d) agreed to issue upon the six month anniversary of the date of the agreement, provided the consultant is still engaged at the respective time of issuance, a warrant to purchase 25,000 shares of our common stock with an exercise price of $10.00 per share, which warrant will have an exercise period of 24 months from the date of the agreement. The warrants (each a “July 2018 Consultant Warrant”) issued under this agreement are callable by us.

In July 2018, we entered into an amendment to a consulting agreement pursuant to which we issued (a) 30,000 shares of our common stock on July 3, 2018, and (b) a warrant on July 3, 2018 to purchase 90,000 shares of our common stock with an exercise price of $8.50 per share. The warrant (the “May 2017 Additional Consultant Warrant”) issued under the amendment ot the consulting agreement has a five (5) year term.

In July 2018, we entered into a consulting agreement with an investor relations firm, pursuant to which we issued two warrants on August 8, 2019 to purchase 20,000 shares of our common stock in the aggregate, with an exercise price of $2.66 per share (the “August 2019 Consultant Warrants”). The August 2019 Consultant Warrants have a three (3) year term and a cashless exercise provision. The August 2019 Consultant Warrants were amended on November 13, 2019 to accelerate the original vesting terms therein such that all warrant shares are exercisable on November 30, 2019, and remain exercisable through the three (3) year term. The August 2019 Consultant Warrants were issued on substantially the same form as our Form of June 2018 Consultant Warrant, filed asExhibit 4.1 of our Quarterly Report on Form 10-Q filed with the SEC on August 13, 2018, and incorporated herein by reference.

In August 2019, we entered into a consulting agreement with an executive search firm, which superseded the July 2018 consulting agreement with the same executive search firm, pursuant to which we issued a warrant on November 8, 201813, 2019 to purchase 7,9176,333 shares of our common stock, with an exercise price of $5$3.00 per share. The warrantshare (the “November 20182019 Consultant Warrant”) issued under the consultant agreement. The November 2019 Consultant Warrant has a three (3) year term. The November 2019 Consultant Warrant was issued on substantially the same form as our Form of November 2018 Consultant Warrant, filed asExhibit 4.4 of our Quarterly Report on Form 10-Q filed with the SEC on November 14, 2018, and incorporated herein by reference.

 

Securities Act Exemptions

 

We deemed the offers, sales and issuances of the securities described above to be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Section 4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, relative to transactions by an issuer not involving a public offering.

 

All certificates representing the securities issued in the transactions described above included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer of the securities.


Use of Proceeds from Registered Securities

On February 13, 2018, our registration statement on Form S-1 (Registration No. 333-222441) was declared effective by the SEC for our IPO pursuant to which we sold an aggregate of 3,500,000 shares of our Common Stock at a price to the public of $5.00 per share, for an aggregate offering of approximately $17.5 million. Piper Jaffray & Co. acted as the sole book-running manager and Oppenheimer& Co. acted as lead manager for the offering. On February 16, 2018, we closed the sale of 3,500,000 shares, resulting in net proceeds to us of $15 million after deducting underwriting discounts and commissions and other offering expenses. On March 12, 2018 we closed the sale of an additional 56,000 shares pursuant to the Partial IPO Over-Allotment Exercise, resulting in net proceeds to us of approximately $258,000 after deducting underwriting discounts and commissions. No payments were made by us to directors, officers or persons owning ten percent or more of our Common Stock or to their associates, or to our affiliates. There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on February 15, 2018 pursuant to Rule 424(b).

Item 3.Defaults Upon Senior Securities.

Item 3. Defaults Upon Senior Securities.

 

None.

Item 4.Mine Safety Disclosures.

Item 4. Mine Safety Disclosures.

 

Not applicable.

Item 5.Other Information.

Item 5. Other Information.

 

None.


Item 6.Exhibits

 

 Exhibit   Incorporated by Reference Filed
Number Exhibit Description Form File No. Exhibit Filing Date Herewith
             
4.1 Form of June 2018 Consultant Warrant.  10-Q 001-38389   4.1 8/13/2018   
             
4.2 Form of May 2017 Additional Consultant Warrant.  10-Q 001-38389   4.2 8/13/2018   
             
4.3 Form of July 2018 Consultant Warrant.  10-Q 001-38389   4.3 8/13/2018   
             
             
4.4 

Form of November 2018 Consultant Warrant.

 

         X
10.1† Employment Agreement, effective October 1, 2018, between the Company and Timothy P. Moran. 8-K 001-38389 10.1 9/25/2018  
             
10.2† Amended and Restated Employment Agreement, effective September 24, 2018, between the Company and Mark Pomeranz. 8-K 001-38389 10.2 9/25/2018  
             
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
32.1** Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350).         X
             
101.1 XBRL Instance Document.         X
             
101.2 XBRL Taxonomy Extension Schema Document.         X
             
101.3 XBRL Taxonomy Extension Calculation Linkbase Document.         X
             
101.4 XBRL Taxonomy Extension Definition Linkbase Document.         X
             
101.5 XBRL Taxonomy Extension Label Linkbase Document.         X
             
101.6 XBRL Taxonomy Extension Presentation Linkbase Document.         X
             
Exhibit   Incorporated by Reference Filed
Number Exhibit Description Form File No. Exhibit Filing Date Herewith
             
4.1 Form of June 2018 Consultant Warrant 10-Q 001-38389 4.1 8/13/2018  
             
4.2 Form of November 2018 Consultant Warrant 10-Q 001-38389 4.4 11/14/2018  
             
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
32.1** Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350).         X
             
101.1 XBRL Instance Document.         X
             
101.2 XBRL Taxonomy Extension Schema Document.         X
             
101.3 XBRL Taxonomy Extension Calculation Linkbase Document.         X
             
101.4 XBRL Taxonomy Extension Definition Linkbase Document.         X
             
101.5 XBRL Taxonomy Extension Label Linkbase Document.         X
             
101.6 XBRL Taxonomy Extension Presentation Linkbase Document.         X

Indicates management contract or compensatory plan.

**Furnished, not filed.


EXHIBIT INDEX

 

 Exhibit   Incorporated by Reference Filed
Number Exhibit Description Form File No. Exhibit Filing Date Herewith
             
4.1 Form of June 2018 Consultant Warrant.  10-Q 001-38389   4.1 8/13/2018   
             
4.2 Form of May 2017 Additional Consultant Warrant.  10-Q 001-38389   4.2 8/13/2018   
             
4.3 Form of July 2018 Consultant Warrant.  10-Q 001-38389   4.3 8/13/2018   
             
4.4 Form of November 2018 Consultant Warrant.         X
             
10.1† Employment Agreement, effective October 1, 2018, between the Company and Timothy P. Moran. 8-K 001-38389 10.1 9/25/2018  
             
10.2† Amended and Restated Employment Agreement, effective September 24, 2018, between the Company and Mark Pomeranz. 8-K 001-38389 10.2 9/25/2018  
             
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
32.1** Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350).         X
             
101.1 XBRL Instance Document.         X
             
101.2 XBRL Taxonomy Extension Schema Document.         X
             
101.3 XBRL Taxonomy Extension Calculation Linkbase Document.         X
             
101.4 XBRL Taxonomy Extension Definition Linkbase Document.         X
             
101.5 XBRL Taxonomy Extension Label Linkbase Document.         X
             
101.6 XBRL Taxonomy Extension Presentation Linkbase Document.         X
             

Indicates management contract or compensatory plan.

**Furnished, not filed.

*Filed herewith.
**Furnished, not filed.

Exhibit   Incorporated by Reference Filed
Number Exhibit Description Form File No. Exhibit Filing Date Herewith
             
4.1 Form of June 2018 Consultant Warrant 10-Q 001-38389 4.1 8/13/2018  
             
4.2 Form of November 2018 Consultant Warrant 10-Q 001-38389 4.4 11/14/2018  
             
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).         X
             
32.1** Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350).         X
             
101.1 XBRL Instance Document.         X
             
101.2 XBRL Taxonomy Extension Schema Document.         X
             
101.3 XBRL Taxonomy Extension Calculation Linkbase Document.         X
             
101.4 XBRL Taxonomy Extension Definition Linkbase Document.         X
             
101.5 XBRL Taxonomy Extension Label Linkbase Document.         X
             
101.6 XBRL Taxonomy Extension Presentation Linkbase Document.         X
             
**Furnished, not filed.         

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 Motus GI Holdings, Inc.
  
Date: November 13, 201814, 2019By:/s/ Timothy P. Moran
 Name:Timothy P. Moran
 Title:Chief Executive Officer and Director
  (Principal Executive Officer)
   
Date: November 13, 201814, 2019By:/s/ Andrew Taylor
 Name:Andrew Taylor
 Title:Chief Financial Officer
  (Principal Financial Officer and Chief Accounting Officer)

 

36

 34